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CHAPTER 1 
General introduction
Partly adapted from: L.B.J. van Iersel, H. Gelderblom, 
J.W.R. Nortier, C.J.H. van de Velde.
Silberman & Silberman, Principles and Practice of Surgical Oncology, 
Second edition 2009; Ch. 48: p882-p891: Liver Tumors: Multi-modality 
treatment of hepatic metastases
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Multimodality treatment of colorectal liver metastases
The most common origin of hepatic metastasis is colorectal cancer. Liver metastases 
are diagnosed in 10-25% of patients at the time of resection of their primary colorectal 
tumour and eventually up to 70 % of patients with colorectal cancer will develop liver 
metastases 1. In approximately 30% of the patients the liver is the only site of metastatic 
disease 2, 3 . If the metastases are confi ned to the liver there are several locoregional treat-
ment options, including partial hepatic resection, local ablative therapy, administration 
of chemotherapy by hepatic artery infusion (HAI) and isolated hepatic perfusion (IHP) 
with high dose chemotherapy. Curative resection of colorectal cancer liver metastases 
is possible in less than 10 percent of patients due to the number, location or size of 
the metastases 4, 5. After neoadjuvant treatment with modern systemic chemotherapy 
regimens another 12-14% of colorectal cancer patients with liver metastases are suitable 
for hepatic resection 6. If patients are ineligible for hepatic resection, palliative systemic 
chemotherapy is often the only treatment option for liver metastases. The role of locore-
gional treatment options other than resection is currently subject to much debate.
Local ablative therapy
Several local ablative techniques are available for the treatment of liver metastases. 
Radiofrequency ablation (RFA) is most often applied. Other less frequently applied 
therapies include cryotherapy, hepatic artery embolization (HAE), percutaneous alcohol 
injection (PAI), microwave coagulation therapy (MCT), laser induced thermotherapy 
(LITT), photodynamic therapy (PTD) and radiotherapy. Local ablative therapies provide 
the possibility of local disease control without systemic toxicity.
Radiofrequency ablation
The major advantage of RFA is the selective destruction of tumour tissue without signifi -
cant damage to normal liver tissue. In RFA, the needle electrodes cause hyperthermia, 
through the delivery of a high frequency alternating current, resulting in the destruction 
of proteins and cell membranes, inducing coagulative necrosis. Under optimal condi-
tions current RFA devices can provide spherical lesions of up to 7cm in diameter 7. RFA 
can be applied alone or in combination with surgical resection if surgical resection 
criteria are not fulfi lled, widening the applicability of surgical resection. Most studies 
on RFA focus around colorectal liver metastases, neuroendocrine tumours and breast 
cancer. Results are often diffi  cult to interpretate, because reports include diff erent 
tumour types, treated with a variety of techniques and additional treatments such as 
chemotherapy obscure the primary eff ect of RFA treatment.
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In colorectal cancer liver metastases, RFA has resulted in complete response rates of 
52-95%, with a median survival time of approximately 30-34 months after diagnosis of 
liver metastases. Local recurrence rates (lesion-based) vary between 2.0-39% depending 
on which method is applied 8-18. Several studies have shown local recurrence rates to be 
less if an open or laparoscopic technique is applied as compared to the percutaneous 
method 19, 20. Over 90% of the recurrent disease occurs outside the treated area both 
intra- and extrahepatically, emphasizing the local nature of the treatment. Optimal 
results in RFA are achieved in an experienced centre, using an open technique, on 3 or 
less liver metastases, not located near any large vascular structures and less than 5cm in 
diameter 18, 21, 22.
The possibility of curation and the large percentage of extrahepatic recurrences after 
RFA have resulted in the common practice of combining systemic treatment with RFA, 
even though the benefi ts of combining both treatments have not been thoroughly 
examined. The true value of RFA remains to be seen.
Other ablative treatment modalities
Cryoablation results in tumour destruction through the formation of intra- and extracel-
lular ice crystals by repeated freezing and thawing, caused by inserting a probe with 
circulating liquid nitrogen. Cryoablation is most frequently applied in the treatment 
of hepatocellular carcinoma (HCC) and to a lesser extent in colorectal cancer liver 
metastases. In colorectal cancer patients a median survival of around 26 months after 
cryoablation has been published 23-26. Cryotherapy has been replaced by other ablative 
treatment modalities, due to the high rates of local recurrences and complications 27, 28.
Hepatic arterial ligation and (chemo)embolization are based on the principle that, liver 
metastases derive most of their blood supply from the hepatic artery, while healthy liver 
tissue is mainly supplied by the portal vein 29, 30. Although ligation and embolization 
were considered promising treatments at introduction several decades ago, no studies 
have shown substantial benefi t in the treatment of liver metastases 31. Therefore many 
centres have abandoned this technique.
Percutaneous alcohol injection (PAI) is mainly applied in the treatment of HCC with 
tumour response rates up to 80%, but its role in the treatment of liver metastases seems 
limited 32. As shown by the poor results of PAI in colorectal liver metastases, with no 
necrosis induced in a series of 22 colorectal tumours, the more solid aspect of colorectal 
liver metastases, can impair the adequate injection of suffi  cient volumes of alcohol in 
the tumour 33.
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Microwave coagulation therapy (MCT) and laser induced thermotherapy (LITT) resem-
ble the RFA technique, as they are based on the generation of heat in the tumour and 
therefore considered thermal ablation techniques. In MCT heat is generated through 
a microwave-emitting needle, producing dielectric heat by stimulation of water mol-
ecules within cells. The rapid agitation of water molecules produces frictional heating 
and coagulative necrosis 34. Like RFA and LITT, MCT can be performed percutaneously, 
laparoscopically or during an open procedure. The major drawback of MCT is it produces 
zones of only 10-25mm of coagulative necrosis, requiring multiple needle insertions 
for adequate treatment. Few studies have been performed using MCT as a treatment 
modality in liver metastases. In colorectal cancer liver metastases, studies have shown 
tumour response up to 87% with a mean survival of 27 months, but patient numbers 
are small 35, 36 In LITT heat is not generated by high frequency current but by a laser 
applicator that delivers light energy through optical fi bers inserted in the target tissue, 
leading to tumour destruction 34. Mack et al reported the largest series of 705 patients, 
including 57% colorectal cancer patients, 18% breast cancer patients, 5% hepatocellular 
carcinoma patients and 20% other patients 37-39 . The rate of clinically relevant complica-
tions such as pleural eff usion, intrahepatic abscess and intra-abdominal bleeding was 
1.3%. The tumour response rate was 99.3% after 3 months, with a mean survival rate in 
respectively colorectal cancer and breast cancer patients of 41.8 and 51.6 months.
PDT, on the other hand, uses optical fi bers and laser light. The antitumor eff ect in PDT 
is caused by reactive oxygen species, generated through a photosensitizing agent, 
which is administered systemically and will localize in tumour tissue 40, 41. Illumination 
of the tumour by light of an appropriate wavelength will cause the photosensitizer to 
transform to an unstable higher energy level. The absorbed energy is transformed to 
oxygen, leading to the formation of reactive oxygen species, which are cytotoxic and 
cause direct tumour cell and vascular damage42. Results of a phase I trial in 24 patients 
show PDT to be feasible and a relatively safe and eff ective treatment of colorectal liver 
metastases 43.
Application of external radiotherapy for the treatment of liver metastases has been 
limited by low tolerance of the normal liver parenchyma and absence of an obvious 
survival benefi t in studies involving whole-liver irradiation 44. Recently two alternative 
techniques to deliver radiation more selectively have been developed involving radio-
active isotopes, i.e. SIR-spheres® and 3D planning software. In selective internal radiation 
therapy (SIRT) radioactive spheres are delivered selectively to the tumour through 
injection in the hepatic artery. Gray et al performed a randomized clinical trial in 74 
colorectal cancer patients comparing a single administration of SIR-spheres® combined 
with hepatic artery infusion of FUDR with hepatic artery infusion of FUDR alone 45. Treat-
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ment with SIR-spheres® was associated with a signifi cantly better response rate (44% vs. 
17.6%, P = 0.01) and median time to progression (15.9 vs. 9.7 months, P = 0.001). Grade 
3-4 treatment related toxicity was similar for both groups. In stereotactic radiotherapy 
improvements in positioning and 3D planning software have enabled treatment of a 
specifi c focus in the liver with a single high dose of radiotherapy with minimal damage 
to healthy liver tissue 34, 46. A phase I/II trial in 60 liver tumours of various origin, show the 
technique is safe and local tumour control was achieved in 98% of tumours 47.
Chemotherapy
 Systemic chemotherapy
Until recently, the standard treatment for metastatic colorectal cancer consisted of 5-FU 
based schedules, resulting in response rates around 15%, median time to progression 
of 5 months and overall survival of 12 months 48. In the past decade several new agents 
have become available including oxaliplatin, irinotecan and the monoclonal antibod-
ies bevacizumab and panitumumab/cetuximab 49-56. Both irinotecan and oxaliplatin 
combined with 5-FU/leucovorin or capecitabine have shown an increase in terms of 
progression-free survival, overall survival and quality of life compared with 5-FU/
leucovorin alone in fi rst- and second-line therapy 54, 56-61. Recently, several studies have 
been conducted investigating combination and sequential use of several new agents. 
Tournigand et al conducted a phase III cross-over study of fi rst-line chemotherapy with 
in one arm 5-FU/leucovorin with oxaliplatin and in the other arm 5-FU/leucovorin with 
irinotecan resulting in maximum medium survival of 21.5 months 52. Even more recently 
Koopman et al showed that both combination treatment and sequential treatment 
with capecitabine, irinotecan and oxaliplatin yields similar results 62. The introduction 
of bevacizumab, a monoclonal antibody directed against vascular endothelial growth 
factor (VEGF) has further improved treatment options in metastatic colorectal cancer. 
Hurwitz et al reported that the addition of bevacizumab to bolus irinotecan and 5-FU/
leucovorin as a fi rst-line treatment resulted in increased survival, response rate and dura-
tion of response 53. Similarly, panitumumab/cetuximab, monoclonal antibodies against 
epidermal growth factor receptor (EGRF) have further improved survival in combina-
tion with either irinotecan or oxaliplatin, especially in patients without K-ras mutation 
49, 55. Now oncologists are faced with the challenge of choosing the optimal treatment 
schedule for advanced colorectal cancer for each individual patient. Currently, the com-
bination of fl uoropyrimidine-based chemotherapy with oxaliplatin and bevacizumab is 
considered standard fi rst-line treatment in metastatic colorectal cancer. The addition of 
panitumumab or cetuximab to a schedule with bevacizumab increases toxicity without 
improving survival and thus should be reserved for second-line treatment 63, 64.
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Regional chemotherapy
Hepatic artery infusion (HAI) is a therapeutic option for patients with isolated liver 
metastases not suitable for surgical resection or local ablation. Similar to hepatic arte-
rial ligation and embolization, HAI of chemotherapy is based on the principle that, in 
contrast to normal liver parenchyma, liver metastases derive most of their blood supply 
from the hepatic artery 29, 30. Subsequently, high drug concentrations can be achieved at 
the tumour site without damage to the healthy liver tissue. HAI has mainly been applied 
in colorectal cancer liver metastases and hepatocellular carcinoma. Early infusion trials 
administered chemotherapy using percutaneously placed catheters, requiring bed rest 
and hospitalization during infusion of the chemotherapy. When a totally implantable 
pump was introduced HAI chemotherapy changed into a more convenient ambula-
tory treatment. All techniques require an angiogram to assess vascular anatomy before 
catheter placement. Most studies show around 20-40% of patients cannot receive infu-
sion treatment due to abnormal vasculature inhibiting perfusion of the entire liver 65-67. 
Catheters and pumps can be placed through laparotomy or laparoscopy. Laparotomy 
enables assessment of extrahepatic metastases and ligation of arterial collaterals to 
decrease incidence of extrahepatic perfusion and chemical gastritis or duodenitis 68, 69. 
Complications associated to catheter placement include death, hepatic misperfusion, 
catheter obstruction and hepatic artery thrombosis, with complications rates being less 
for implantable pumps as compared to ports 68, 70, 71.
Fluorodeoxyuridine (FUDR) and 5-FU are the drugs most often used for hepatic arte-
rial infusion. An ideal drug for HAI has to fulfi l several criteria including a steep dose 
response curve, high total body clearance and minimal liver toxicity. Both FUDR and 
5-FU have a steep dose response curve, but FUDR has a higher hepatic extraction rate 
when continuously infused (95% for FUDR vs. 19-90% for 5-FU ) 72. Although higher 
hepatic extraction rates lead to increased regional drug exposure, it also implies limited 
systemic exposure. Considering approximately 50% of patients treated with HAI have 
extrahepatic disease progression, some centres prefer HAI with 5-FU to obtain both 
local and systemic disease control 73. Treatment-related toxicities include chemical 
hepatitis, biliary sclerosis and peptic ulceration. Kemeny et al reported an increase in 
response and survival rate and a decrease in hepatotoxicity if dexamethasone is added 
to FUDR 74. Several randomized studies involving HAI with FUDR or 5-FU in colorectal 
cancer patients have reported signifi cantly higher tumour response rates compared 
with systemic administration (HAI 41%, systemic 14%; p<0.0001) 65, 66, 75. In 1996, two 
meta-analyses combining the results of 10 randomized trials appeared, comparing HAI 
with either systemic treatment or best supportive care 73, 76. The Meta-Analysis Group 
in Cancer studied 7 randomized trials and when combining the results of the 5 trials 
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comparing HAI with systemic treatment, concluded that although HAI showed superior 
response rates compared to systemic treatment (41% vs.14%) there was no signifi cant 
survival benefi t and treatment-related hepatotoxicity was considerable. Harmantas et al 
studied 6 randomized trials and reported a modest survival benefi t for HAI over systemic 
treatment. These studies have two major drawbacks. First of all, in three of the analyzed 
randomized trials patients were allowed to cross-over from systemic treatment to HAI 
possibly obscuring any survival benefi t. Secondly, the drug doses and schedules varied 
substantially between HAI and systemic treatment groups. A recent randomized study 
in which 290 colorectal cancer patients were included also did not show signifi cant dif-
ferences in tumour response , progression-free survival and overall survival between 
patients who had received 5-FU/leucovorin either systemically or by HAI, while the HAI 
group reported a worse quality of life compared with the systemically treated group 
77. On the other hand Kemeny et al published a trial in 135 colorectal cancer patients 
and reported a signifi cant survival benefi t (median overall survival 24.4 vs. 20 months, 
P= 0.0034) and increased physical functioning in patients receiving HAI compared to 
systemic treatment 78.
 Recently several new drugs like for example oxaliplatin and irinotecan have been safely 
introduced in HAI 79-84. Results of a phase I/II study on biweekly HAI with oxaliplatin 
combined with systemic 5-FU en leucovorin according to the de Gramont schedule 
were recently reported by Ducreux et al 85. A total of 28 previously untreated patients 
with colorectal cancer with isolated liver metastases were treated with this schedule, the 
objective response rate was 64% and the median overall survival was 27 months. Grade 
3 or 4 neutropenia occurred in 10 patients and there were two treatment related deaths. 
Compared to local ablative treatments HAI of chemotherapy can off er the additional 
benefi t of both local and systemic disease control. In colorectal cancer liver metastases 
meta-analysis and recent randomized trials show confl icting results, but most trial de-
signs did not allow for correct comparison of both treatment groups. Moreover, recent 
developments in new systemic drugs like oxaliplatin, irinotecan, bevacizumab and 
cetuximab/panitumumab have improved results substantially in the systemic treatment 
over liver metastases. If these agents have a role in HAI remains to be investigated.
Isolated hepatic perfusion
Isolated hepatic perfusion (IHP) involves complete vascular isolation of the liver to allow 
local treatment of the liver. During this procedure the blood circulation of the liver is 
temporarily isolated from the systemic circulation. Infl ow catheters are inserted in the 
common hepatic artery and the portal vein and an outfl ow catheter in the infrahepatic 
caval vein while the suprahepatic caval vein is occluded by a surgical clamp. Subse-
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quently the catheters are connected to heart-lung machine and the anticancer drug is 
administered in this isolated circuit. Leakage to the systemic circulation is monitored in 
order to prevent high systemic exposure. After perfusion of the liver with the drug for a 
certain period of time (1 hour in most IHP trials) the liver is fl ushed with clean perfusate 
to wash out the anticancer drug after which the natural blood circulation is restored 86.
The major advantage of IHP is the ability to treat the liver with drug levels that would be 
toxic when administered systemically 86. Moreover, agents which cannot be administered 
systemically because of their toxicity, such as tumour necrosis factor alpha (TNF-α), can 
be used in IHP 87, 88. Furthermore, hyperthermia, which is known to improve the anti-
cancer eff ect of several drugs, can be applied by heating the perfusate solution 89.
Most experience with IHP has been obtained with colorectal liver metastases, but 
several studies have reported the treatment of uveal melanoma and neuroendocrine 
cancer liver metastases 87, 88, 90-94. Various drugs have been used in IHP studies, including 
5-FU, mitomycin C, cisplatin and melphalan with or without TNF-α. Usually mild hyper-
thermia is applied up to 40oC during IHP, although one study investigates the effi  cacy of 
hyperthermia alone (42-42.5oC). Recent clinical studies have mainly applied melphalan 
in IHP. Two large trials have been reported in colorectal cancer patients. Bartlett et al 
have reported IHP in 51 patients with diff erent treatment schedules, including IHP with 
high doses of melphalan alone and moderately high doses of melphalan combined with 
TNF-α or followed by monthly hepatic intra-arterial infusion of FUDR and leucovorin 94. 
Results of these studies show response rates up to 74%, a median time to progression up 
to 14.5months and a median survival of 27 months. Rothbarth et al performed a phase 
I/II trial in 73 colorectal cancer patients with high dose melphalan, achieving an overall 
response rate of 59%, median time to progression of 7.7 months and a median overall 
survival of 28.8 months 93. In uveal melanoma patients, IHP has resulted in response rates 
of 50-62%, with a median overall survival of 9.9-12 months87, 90, 92. The nature and inci-
dence of major complications was similar in all trials independent of primary origin of 
liver metastases. Mortality rate varied between 2-5% and major complications consisted 
of bleeding and hepatoxicity including veno-occlusive disease.
Melphalan has been the only agent applied in major clinical trials over the past 10 
years. Over the past few years new agents like irinotecan, oxaliplatin and bevacizumab, 
have been introduced in the systemic treatment of colorectal metastases, increasing 
response rates, disease free survival and overall survival 51-53, 95. Ideally some of the devel-
opment in the systemic treatment of colorectal cancer metastases can be incorporated 
in isolated hepatic perfusion. Despite encouraging results in recent trials, IHP should 
still be considered an experimental treatment. No prospective trials have been reported 
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comparing IHP to either systemic treatment or local ablative treatment and little is know 
about the role of adjuvant systemic treatment. Whether IHP will eventually become a 
standard treatment option is highly depended on the introduction of new drugs in 
order to further increase eff ectiveness, as recently shown for systemic treatment, and 
the development of new techniques with less mortality and improved responses.
Outline of this thesis
The aim of this thesis was to study the role of IHP in the treatment of liver metastases 
and to evaluate possible improvements to IHP.
In chapter 2, IHP is evaluated as a treatment option for liver metastases from non-
colorectal origin. In chapter 3, the safety and effi  cacy of a new drug administration in IHP 
through infusion is assessed. While in chapter 4, possible prognostic factors for IHP are 
identifi ed to further improve patient selection. To establish the role of IHP, we compared 
IHP with systemic treatment in colorectal cancer patients with liver metastases only in 
chapter 5. Chapters 6 and 7 report the results of our eff orts to introduce the new agent 
oxaliplatin as a possible drug in IHP for colorectal cancer liver metastases.
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Abstract
The liver is one of the most common sites for metastatic solid tumours. If the liver is the 
only site of metastatic disease, regional treatment options can off er the benefi t of high 
local exposure with limited systemic toxicity, especially for patients without (further) 
systemic treatment options. We report the results of our experience with isolated he-
patic perfusion (IHP) in patients with isolated liver metastases from a variety of primary 
tumours.
Nineteen patients with isolated unresectable liver metastases from a variety of tumours 
(13 uveal melanomas, 2 neuroendocrine carcinomas, 2 gastrointestinal stromal tumours, 
1 hepatocellular carcinoma and 1 high grade sarcoma) were treated with a 60-minute 
IHP using 200 mg melphalan. Patients were monitored for toxicity, response according 
to RECIST criteria and survival.
One melanoma patient was not perfused due to insuffi  cient isolation of the liver. There 
was no treatment-related mortality. Reversible grade 3 to 4 hepatoxicity occurred in 10 
(56%) patients, while veno-occlusive disease occurred in 4 (22%) patients. Of the twelve 
uveal melanoma patients who were perfused, 4 (33%) patients had a partial hepatic 
response, 6 (50%) patients had stable hepatic disease and 2 (17%) patients were imme-
diately progressive. Median disease-free survival was 6.6 months with a median overall 
survival of 10.0 months. Fifty percent of other primary tumours showed at least partial 
remission, including 1 complete remission in a high grade sarcoma patient.
IHP with melphalan shows activity in patients with liver metastases from a variety of 
primary tumours, but other or additional drugs may improve therapeutical outcome.
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Introduction
The liver is one of the most common sites for metastatic disease and is involved in ap-
proximately 40% of adult patients with primary extrahepatic malignant disease who 
undergo an autopsy. The most common origin of hepatic metastasis confi ned to the 
liver is colorectal cancer. Neuroendocrine tumours and uveal melanomas, although rare, 
are the second most common origin of metastases confi ned to the liver1. Gastrointes-
tinal neuroendocrine tumours are predominantly carcinoids (55%), consisting mainly 
of midgut carcinoids (50-70%) which have the greatest potential for metastasizing to 
the liver 2, 3. Uveal melanoma is the most common primary intraocular tumour in adults, 
with an incidence of 5-7 per 1 million per year in the Western population 4. Nearly up to 
50% of patients will ultimately develop metastases, of which more than 60% is confi ned 
to the liver 5, 6. Other primary tumours that may initially metastasize exclusively to the 
liver include gastrointestinal stromal tumours (GIST) and even more rarely renal cell 
carcinoma, Wilms’ tumour and breast cancer. Although liver metastases from primary 
tumours such as cancers of the lung, breast, stomach and cutaneous melanoma may 
occur more frequently, dissemination usually occurs simultaneously to other visceral 
locations.
If the metastases are confi ned to the liver several locoregional treatment options can be 
considered, including partial hepatic resection, radiofrequency ablation (RFA), adminis-
tration of chemotherapy by hepatic artery infusion (HAI) and isolated hepatic perfusion 
(IHP) with high dose chemotherapy. Curative resection is possible in only a small fraction 
of patients due to the number, location or size of the metastases 7, 8. RFA is mainly suit-
able for patients with a limited number of liver metastases that are not located near any 
large vascular structures and less than 5cm in diameter 9-11. Compared to HAI, IHP off ers 
the benefi ts of high local drug exposure with limited systemic toxicity 12.Various studies 
have been published on IHP for colorectal liver metastases 13-15, but only a few studies 
have been reported on IHP for liver metastases from other primary tumours 16-20.
In this study we present our experience with 19 patients with a variety of primary tu-
mours other than colorectal cancer, including uveal melanoma, high grade sarcoma and 
GIST, who underwent IHP at the Leiden University Medical Center.




Between May 1995 and May 2006, 19 patients with liver metastases of uveal melanoma 
(13), GIST (2), hepatocellular carcinoma (1), neuroendocrine carcinoma (2) and high 
grade sarcoma (1) were treated with IHP with 200mg melphalan according to a study 
protocol approved by the local ethics committee. Using the same melphalan dose, 
during the accrual period, IHP was performed in 105 patients with colorectal cancer 
hepatic metastases 13, 15, 21, indicating feasibility and our experience with this procedure. 
Informed consent was obtained from all patients. The tumour response of 8 uveal 
melanoma patients has been previously reported 16. Eligibility criteria included a WHO 
performance status of 0 or 1, leukocyte count ≥ 3.0 × 109/L, platelet count ≥ 100 × 109/L, 
maximum serum creatinine level 135 μmol/L, maximum bilirubin level 17 μmol/L and 
minimum albumin level 40 g/L. Exclusion criteria were age over 70 years, life expectancy 
of less than 4 months, more than 60 percent hepatic replacement by tumour tissue as es-
timated from the preoperative abdominal CT scan, coagulation disorders and evidence 
of extrahepatic metastatic disease. All patients had a preoperative chest and abdominal 
computer tomography (CT), full blood count, liver function tests, and determination of 
lactate dehydrogenase, albumin and creatinine and electrolytes.
IHP technique
Briefl y, the liver was mobilized from the diaphragm through a transverse abdominal 
incision. The common hepatic artery (8-Fr 77008 one-piece pediatric arterial cannula; 
Medtronic, Minneapolis, Minnesota, USA) and the portal vein (12-Fr perfex perfusion 
catheter CH12; B. Braun Medical, Oss, The Netherlands) were cannulated and connected 
to a heart-lung machine which consisted of two independent roller pumps (model 
10-30-00; Cobe/Stöckert, Munich, Germany). For 14 patients both the hepatic artery 
and portal vein were used for infl ow of melphalan in the isolated circuit, because this 
technique was used in our previously reported phase I 15 and II 13 study. Although there 
is no established benefi t from drug delivery by using the portal vein during our IHP 
procedure oxygenated blood is perfused through the portal vein and this may possibly 
prevent hypoxia induced damage to the liver. Moreover, by using our technique, the MTD 
of melphalan is much higher than reported by other groups who only used the hepatic 
artery for drug delivery. For 5 patients we used hepatic artery infusion at reduced fl ow as 
reported in a recent publication 22. The inferior vena cava (IVC) was cross-clamped above 
the hepatic veins and cannulated proximal of the renal veins (Polystan 36 Fr, straight, 
A/S, Värlöse, Denmark) to allow undisturbed blood fl ow from the hepatic veins through 
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the IVC towards the heart-lung machine. To isolate the hepatic circuit, tourniquets were 
secured around the hepatic artery, portal vein and IVC.
For the extracorporeal venovenous bypass, the right femoral vein (22-Fr cannula DI-
ITF022L; Edwards Lifesciences, Irvine, California, USA) and the portal vein (17-Fr perfex 
perfusion catheter CH17; B. Braun) (proximal to the tourniquet) were cannulated and 
connected to the right axillary vein (18-Fr 7326 perfusion cannula; Lifestream Inter-
national, The Woodlands, Texas, USA). The venovenous bypass was supported by a 
centrifugal pump (Medtronic BIO-Medicus, Eden Prairie, Minnesota, USA) and primed 
with 700 mL 0.9 % saline. The perfusion medium consisted of intrahepatically trapped 
blood and 1250 mL Gelofusine® (Vifor Medical, Sempach, Switzerland) plus 2500 units 
heparin (Leo Pharma, Breda, The Netherlands) to yield a fi nal volume of approximately 
2 litres. Throughout the 1-h perfusion interval, the perfusate was kept at a temperature 
of 39·5 °C by a heat exchanger and oxygenated using an oxygenator (Cobe VPCML; 
Cobe Cardiovascular, Arvada, Colorado, USA) except for the last 3 patients who were 
oxygenated using a diff erent oxygenator (Dideco D901, SORIN group Italia, Mirandola, 
Italy). After perfusion, the liver was fl ushed for approximately 10 minutes with 3 liters 
Gelofusine®. All cannulas and clamps were removed, and the incisions were closed. To 
prevent possible melphalan induced cholecystitis, cholecystectomy was performed.
Melphalan
Melphalan 200mg (Alkeran®, GlaxoSmithKline, Zeist, The Netherlands) was fi rst dissolved 
in 40 mL Wellcome Diluent (a 60/40 (v/v) mixture of proylene glycol containing 5.2% 
(v/v) ethanol and 0·068 mol/l sodium citrate), which was subsequently diluted with 60 
mL sterile saline. Melphalan was administered as a bolus in the isolated hepatic circuit 
(13,15) and in the last 5 patients through 20 minute infusion using an infusion pump 
(Pilote Anesthesie; Fresenius, Brezins, France) connected to the hepatic artery line of the 
isolated hepatic circuit 22.
Leakage Detection
Leakage of perfusate into the systemic circuit was monitored by adding 10 MBq 99mTc-
pertechnetate to the isolated circuit with subsequent measurement of the level of 
radioactivity in both the systemic and isolated circuit, as described previously 23, 24. If no 
leakage was detected, melphalan was administered: If leakage was calculated to exceed 
10% during the perfusion period, the procedure was stopped and the liver was fl ushed 
just before this level was reached.
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Postoperative Care
All patients received a daily subcutaneous dose of 480 μg granulocyte colony-stimulat-
ing factor (G-CSF) (Filgrastim/Neupogen®; Amgen, Breda, The Netherlands) starting the 
day after the operation until the nadir in leukocyte count was reached and the count 
had risen to more than 1.0 × 109/L. Patients were monitored in the intensive care unit 
for at least 1 day after IHP. Liver and renal function tests and full blood counts were 
carried out daily in the fi rst week and henceforth as indicated by their respective levels. 
Antibiotics in a combination of cefuroxim and metronidazol were given to all patients 
for 5 days after IHP.
Toxicity
Systemic and regional toxicity data were collected prospectively and graded retro-
spectively according to the National Cancer Institute Common Toxicity Criteria version 
2.0. Hepatic toxicities were considered melphalan related if elevations in liver function 
persisted beyond 7 days after perfusion, as previously suggested 25.
Response evaluation
Objective tumour response measurements were obtained by follow up CT scans of the 
liver and remaining abdomen at 3-month intervals after treatment and at 6-month in-
tervals after 1 year. Additional imaging was performed if clinically indicated. All Ct scans 
were revised using RECIST criteria to determine response rates. For the RECIST criteria 
lesions were only considered measurable if ≥10mm, complete response was defi ned 
as disappearance of all known disease, partial response as a reduction in the sum of 
maximal diameters of ≥30%, stable disease as a reduction of <30% or an increase of 
<20% and progressive disease as an increase of ≥20% or the appearance of new intra- or 
extrahepatic lesions 26. Disease-free survival was calculated from the date of IHP until the 
date of local and/or systemic recurrence or death from any cause.
Statistical analysis
All data were analysed with SPSS statistical software (version 14.0. for Windows, SPSS, 
Chicago, IL, USA). The analyses of time to progression and survival were carried out by 
the Kaplan–Meier method. If patients died before hepatic progression had occurred, 
date of death was taken as date of progression.
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Results
Patient and treatment characteristics
Patient and tumour characteristics are listed in Table 1. A total of 19 patients with 
unresectable liver disease and no evidence of extrahepatic disease were considered 
eligible for IHP. Thirteen patients presented with an uveal melanoma as primary tumour, 
2 patients with a GIST, 2 patients with a neuroendocrine carcinoma, 1 patient with a he-
patocellular carcinoma (HCC) and 1 patient with a high grade sarcoma. Sixteen patients 
presented with metachronous liver metastases. The mean number of liver metastases 
was 24 (range 1 to >100) with a mean estimated hepatic replacement of 23% (range 5% 
to 50%). Mean time from diagnosis of liver metastases to IHP was 4.3 months (range 0.7 
to 13.7 months). Five patients received chemotherapy prior to IHP.
All 19 patients underwent IHP, but in 1 patient the procedure failed due to failure to ob-
tain suffi  cient isolation of the liver and this patient was excluded from further analyses. 
Treatment characteristics of the remaining 18 patients are similar to our previous experi-
ence with colorectal cancer patients and are listed in Table 2 13. The median operating 
time was 8 hours and 7 minutes, with a median blood loss of 3.5 liters (range 1-8 L). The 
median hospital stay was 11 days (range 7-25 days). Median follow up was 74 months 
(range 4 to 137 months).
Table 1 Patient and tumour characteristics
Characteristic n (%)























Mean % of hepatic replacement [range] 23.4 [5 to 50]
Median no. of metastases [range] 12 [1 to >100]
Median time of diagnoses of hepatic metastases to IHP 2 [0.7 to 13.7]
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Toxicity and complications
Ten patients experienced grade 3-4 toxicity of one or more liver enzymes one week 
after IHP as shown in Table 3. This hepatoxicity was transient and only persisted in the 
4 patients that developed veno-occlusive disease (VOD). Major complications occurred 
in 5 patients; as previously mentioned, 4 patients developed signs of VOD and 1 other 
patient experienced a lung embolism. Neutropenia was rare and no neutropenic infec-
tions occurred. Give the low leakage rate G-CSF, which was common practice since early 
development of this procedure in phase I, is deemed unnecessary in future patients. All 
patients left the hospital within 4 weeks.
Tumour response, progression-free and overall survival
The patients with uveal melanoma and the patients with liver metastases from other 
primary tumours were analyzed separately. The details on tumour responses, progres-
sion-free survival and overall survival details of the 6 patients with primary tumours 
Table 2 Treatment parameters
Parameter Mean ± SD
Flow rate hepatic artery (mL/min) 290.4 ± 100
Flow rate portal vein (mL/min) 230.8 ± 97.3
Pressure hepatic artery (mm/Hg) 118.1 ± 24.6
Pressure portal vein (mm/Hg) 36.5 ± 9.3
Percentage leakage during perfusion 2.6 ± 4.9
Blood loss (L) 3.9 ± 2
Operative time (hr) 8.9 ± 1.3
Hospital stay (days) 12.7 ± 4.8
Table 3 Toxicity according to National Cancer Institute Common Toxicity Criteria version 2.0 (n=18)
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other than uveal melanoma are given in Table 4. The high grade sarcoma patient had a 
complete response for 27.1 months while 1 neuroendocrine tumor patient had a partial 
response for 33.4 months and was still alive at the end of follow up.
Of the 12 uveal melanoma patients, 4 (33%) patients had a partial hepatic response, 
6 (50%) patients had prolonged stable hepatic disease and 2 (17%) patients were im-
mediately progressive. Progressive disease occurred in all patients during follow up. 
Six (50%) patients had hepatic progression, 3 (25%) had extrahepatic progression and 
3 (25%) were both hepatic and extrahepatic progressive. Progression-free and overall 
survival curves for uveal melanoma patients are shown in Figure 1. The median time to 
hepatic progression was 8.2 months (range 1.7 to 17.1 months), while median time to 
overall progression after IHP was 6.6 months (range 1.7 to 17.1 months). All but 1 patient 
died during follow up. The median overall survival after IHP was 10 months (range 4.8 
to 47.6 months), with a median overall survival from diagnosis of liver metastasis of 12.2 
months (range 8.7 to 49.6 months).
Discussion
This study shows that IHP with 200mg melphalan shows activity in patients with liver 
metastases of primary tumours other than colorectal cancer. Transient grade 3 to 4 hep-
atotoxicity was observed in 56% of patients, similar to the results of previous studies 19, 
Table 4 Treatment results of IHP with 200mg melphalan in patients with isolated liver metastases of 
primary tumours other than uveal melanoma























Extrahepatic 33.4 89.4a 95.3a
3 GIST Stable 
disease
Extrahepatic 8 36.2 36.9
4 GIST Stable 
disease
Hepatic 13 22 23.8
5 HCC Partial 
remission
Hepatic 5.9 14.4 26.8




Both 27.1 50.2 52
a Patient was still alive at the end of follow up. Data is censored at the end of follow up.
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27. The incidence of VOD (4/18) was relatively high compared to the results in colorectal 
cancer patients. VOD is thought to result from cumulative exposure to chemotherapeu-
tic agents, but only 5 patients in this study received chemotherapy prior to IHP and 
none of them developed VOD 28. The patients with VOD showed similar characteristics 
as compared to the patients without VOD, except for the fact that the incidence of VOD 
was higher (2 out of 5) in the patients treated with hepatic artery infusion at reduced 
fl ow, a technique that was recently abandoned by us because of limited response rates 
and hepatotoxicity . This leaves 3 VODs out of 13 patients treated with with melphalan 
through hepatic artery and portal vein infl ow, which is considered acceptable toxicity. 
Of note, 5% underwent a major laparotomy, but could not be perfused: this was due 
to extrahepatic disease that was not observed on CT-scanning. In order to reduce the 
incidence of unexpected extrahepatic disease on laparotomy, optimal staging with PET-
scanning is being introduced in future patients. Response rates, disease-free and overall 
survival remain diffi  cult to interpret due to small numbers and should be evaluated 
in view of the lack of other treatment options in patients with the tumours that were 






















Fig. 1. Overall and progression-free survival curves for uveal melanoma patients. Of the 13 uveal 
melanoma patients, 12 patients were treated with IHP and included in the progression-free and overall 
survival analysis.
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For the treatment of metastatic uveal melanoma no standard systemic agent currently 
exists. Several studies have reported response rates of less than 10% to conventional 
systemic chemotherapy 29, 30. Results with immunotherapy, as for example interferon-α 
and interleukin-2, are equally disappointing with no or only minor responses 31, 32. Peters 
et al reported the use of HAI with fotemustine, an alkylating agent, in 101 uveal mela-
noma patients with liver metastases 33. Fotemustine was infused in the hepatic artery 
for a 4-week induction period followed by a maintenance treatment every three weeks 
until disease progression. A median of 8 infusions per patient were delivered. Catheter 
related complications occurred in 23% of patients. The overall response rate was 36%, 
with a median overall survival of 15 months and a 2-year survival rate of 29%. Although 
the response rate of fotemustine infusion is similar to our results with IHP in uveal 
melanoma patients, the overall survival of 15 months seems superior to our observed 10 
months. The diff erence could be explained by a diff erence in hepatic tumour load, but 
numbers estimating the tumour burden are not reported. The improved survival could 
also be attributed to the combination with debulking surgery in 38 patients undergoing 
HAI with fotemustine.
Alexander et al reported the results of IHP with 1.5mg/kg melphalan in 29 uveal melano-
ma patients. Hepatic response rate was 62% with a progression-free survival of 8 months 
and an overall survival of 12.1 months. In our patients the response rate was less; only 
33%, but 50% of patients did show stable disease with a median time to progression of 
6.6 months and an overall survival of 10 months similar to the results of Alexander et al. 
Although these results may seem disappointing as compared to IHP in other primary 
tumors, there is a survival benefi t compared to a median survival of 2 months in uveal 
melanoma patients with liver metastases without antitumour treatment 34. Moreover, 
currently we have no accepted alternative treatment options for uveal melanoma pa-
tients with irresectable isolated liver metastases.
Treatment of neuroendocrine liver metastases is aimed at improvement of the hormonal 
symptoms through reduction of tumour burden. Results of systemically administered 
agents have been disappointing in neuroendocrine cancer metastases with response 
rates around 6-40% for cytostatic drugs and 11% for interferon-α 35-38. Symptomatic im-
provement can be achieved in up to 70% of patients with somatostatin analogs such as 
octreotide, but objective tumour response occurs in less than 10% and drug resistance 
can develop in 3-12 months 39-42. Recently attention has shifted to the development of 
radiolabeled somatostatin analogs. Valkema et al reported the response after peptide 
receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in 56 patients with ad-
vanced neuroendocrine tumours 43. Overall, 58% of patients experienced improvement 
of symptoms, the median progression free survival was 29 months with a median overall 
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survival of nearly 37 months. Several studies have been reported on the use of RFA for 
neuroendocrine liver metastases 44-46. In the largest published study the laparoscopic 
ablation of 234 hepatic lesions in 34 patients is reported 47. Symptoms were relieved in 
95% of the patients, with a signifi cant or complete symptom control in 80% of them for a 
mean duration of 10 months. New liver metastases developed in 28% of these patients, 
new extrahepatic disease in 25% and local liver recurrence in 13%, at a mean follow-up 
of 1.6 years. Grover et al reported an overall response rate of 50% with IHP in 13 neuro-
endocrine tumours with a median progression free survival of 7 months 17. Although we 
treated only two patients with neuroendocrine tumours, one patient with a carcinoid 
showed a partial response for 33.4 months. In neuroendocrine carcinoid tumours cau-
tion should be taken to block hormone secretion, because systemic complications have 
been reported during RFA of carcinoids 48.
Imatinib has become the standard fi rst line systemic treatment for advanced GIST. 
GISTs have characteristic gain-of-function mutations in the KIT-oncogene that results 
in overexpression of the KIT-protein (CD117)49. Imatinib is a potent, specifi c KIT/PDGFR-
small molecule tyrosine kinase inhibitor with a patient benefi t rate (prolonged stable 
disease and response) of up to 90% and median progression free survival of 2,5-3years50, 
51. Second-line treatment with sunitinib, an oral multitargeted receptor tyrosine kinase 
inhibitor, can add a median of 8 months in about 60% of patients 52. Before the imatinib/
sunitinib era no systemic treatment options existed for metastatic GIST. Hepatic arterial 
chemoembolization was one of the options for patients with hepatic metastasis derived 
from GIST resulting in a mean survival of 9,5- 11.4 months.53, 54 The addition of RFA to 
transcatheter arterial chemoembolization could increase survival to up to 25 months 55. 
To our knowledge there have been no reports published on IHP for GIST. In our study 
two patients with GIST were included and showed stable disease with a disease-free 
survival of 8 and 13 months respectively and an overall survival of 36.2 and 22 months 
respectively. Both patients were treated prior to the imatinib/sunitinib-era. The above 
mentioned local treatment options, including IHP, can thus be considered in patients 
refractory to imatinib and sunitinib with progressive liver lesions without further extra-
hepatic progression.
In recent studies with IHP, melphalan with or without TNF-α, has been the only che-
motherapeutic agent used. Melphalan is an alkylating-agent that is mainly used in the 
systemic treatment for multiple myeloma, isolated limb, lung and liver perfusion. Little 
is known about the eff ectiveness of systemic melphalan treatment in the tumours de-
scribed above. If IHP is considered as serious treatment option for patients with a variety 
of primary tumours other tumour-specifi c agents need to be studied to improve tumour 
response. Ideally, tumour-specifi c IHP agents should be developed. A wide range of 
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agents is possible because, for example IHP off ers the additional advantage that as long 
as agents are specifi c to the tissue of origin of the primary tumour, they do not have to 
diff erentiate between malignant and healthy tissue due to the local exposure in the liver.
In conclusion, IHP appears to be feasible in patients with liver metastases from a variety 
of primary tumours. To improve responses in IHP, the role of new agents tailored to 
specifi c tumour types needs to be assessed.
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Abstract
Isolated hepatic perfusion (IHP) off ers the advantage of high local drug exposure with 
limited systemic toxicity. To increase local drug exposure, we administered melphalan at 
a reduced fl ow in the hepatic artery during IHP (Hepatic artery Infusion, Hepatic artery-
Portal vein Perfusion, HI-HPP).
Between December 2001 and December 2004, 30 patients with colorectal cancer liver 
metastases underwent HI-HPP with 200mg melphalan. Samples of the perfusate were 
taken for pharmacokinetic analysis. Patients were monitored for response, toxicity and 
survival.
Perfusion was aborted prematurely in 2 patients due to leakage. During melphalan ad-
ministration in the hepatic infl ow cannula a mean fl ow rate of 121.3 mL/min and mean 
pressure of 62.5 mm Hg was achieved. One patient died within 30 days after HI-HPP. 
Four patients developed veno-occlusive disease (VOD), while 2 patients showed signs 
of VOD. Twelve patients showed hepatic response, with a median duration of response 
of 11.5 months, according to WHO criteria.
Although HI-HPP results in high perfusate melphalan concentration levels, it is associ-
ated with a relatively high level of hepatotoxicity and a limited response rate. We believe 
the low fl ow and pressure rates found in this study can result in reduced drug penetra-
tion of the tumour and thus limited tumour response.
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Introduction
Liver metastases are diagnosed in 10-25% of colorectal cancer patients at the time of 
resection of their primary tumour and eventually up to 70 % of patients with colorectal 
cancer develop liver metastases 1. In approximately 30% of the patients the liver is the 
only site of metastatic disease 2, 3. Hepatic resection is considered the treatment of 
choice for colorectal cancer liver metastases with 5-year survival rates ranging from 25-
51%, while 5-year survival after systemic treatment alone remains <1%, emphasizing the 
importance of aggressive liver-directed treatment 4-6. Unfortunately curative resection 
of liver metastases is only possible in less than 10 percent of patients due to the number, 
location or size of the metastases 4, warranting the necessity for other liver-directed 
therapies. Although recent studies have shown improved survival with the introduc-
tion of oxaliplatin, irinotecan, bevacizumab and cetuximab in the systemic treatment of 
colorectal metastases 7-12, regional treatment options can off er the potential benefi t of 
both aggressive local treatment and limited systemic toxicity. Several regional therapies 
have been developed including radiofrequency ablation, hepatic artery infusion (HAI) 
and isolated hepatic perfusion (IHP). In both HAI and IHP high drug concentrations can 
be achieved at the tumour site with relatively low systemic drug exposure. HAI is based 
on the principle that liver metastases derive most of their blood supply from the hepatic 
artery. As a result high drug concentrations can be achieved at the tumour site, while the 
liver parenchyma is relatively spared 13, 14. The systemic exposure in HAI mainly depends 
on the rate of hepatic extraction and metabolization. IHP, on the other hand, involves 
complete vascular isolation of the liver, which allows the use of high dosages that would 
cause fatal complications if delivered systemically. Marinelli et al. showed that in a rat 
model bolus administration of the maximally tolerated doses of melphalan in HAI (6 
mg kg-1) and IHP (12 mg kg-1) resulted in four times higher concentrations in both 
liver and tumour tissue of the IHP treated rats 15. Furthermore, eff ective anti-tumour 
compounds which can not be administered systemically due to their toxicity, such as 
tumour necrosis factor alpha (TNF-α), can be used in IHP. At our institution a phase I/II 
trial was performed in 73 colorectal cancer patients with bolus administration high dose 
melphalan, achieving an overall response rate of 59%, with a median progression-free 
survival of 7.7 months and a median overall survival of 28.8 months, similar to the results 
at other institutions 16-19. Pharmacokinetic analysis of these patients showed that the 
concentration of bolus administered melphalan rapidly declines in the fi rst 5-10 minutes 
of circulation 20. Theoretically, infusing melphalan directly into the hepatic artery over a 
certain period would lead to more selective tumour exposure and prolonged exposure 
of the tumour to high concentrations of melphalan, which can be expected to improve 
antitumour effi  cacy of IHP. Based on the above we developed a Hepatic artery Infusion, 
Hepatic artery-Portal vein perfusion (HI-HPP). In this report, we present the results of 
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30 colorectal cancer patients with irresectable liver metastases treated with isolated 
hepatic perfusion with a 20 minute infusion of melphalan.
Patients and methods
Patient Eligibility
Between December 2001 and December 2004, 30 patients with colorectal cancer con-
fi ned to the liver were treated with HI-HPP with 200mg melphalan. The study protocol 
was approved by the medical ethical committee of the Leiden University Medical Center 
and informed consent was obtained from all patients. All patients had measurable, ir-
resectable colorectal metastases confi ned to the liver. Liver metastases were deemed 
irresectable based on number, size and localization. Standard staging studies were per-
formed including CT scan of the chest and abdomen. Additional MRI or PET scans were 
performed if clinically indicated. Eligibility criteria included a WHO performance status 
of 0 or 1, leukocyte count ≥ 3.0 × 109/L, platelet count ≥ 100 × 109/L, maximum serum 
creatinine level 135 μmol/L, maximum bilirubin level 17 μmol/L and minimum albumin 
level 40 g/L. Exclusion criteria were age over 70 years, life expectancy of less than 4 
months, more than 60 per cent hepatic replacement by tumour tissue as estimated from 
the preoperative abdominal CT scan, coagulation disorders and evidence of extrahepatic 
metastatic disease. The interval between resection of the primary colorectal tumour and 
perfusion had to be at least 6 weeks.
IHP technique
All patients were treated with HI-HPP, consisting of an extracorporeal venovenous by-
pass (see fi gure 1), as described previously 17. Briefl y, the liver was mobilized from the 
diaphragm through a transverse abdominal incision. The common hepatic artery (8-Fr 
77008 one-piece pediatric arterial cannula; Medtronic, Minneapolis, Minnesota, USA) 
and the portal vein (12-Fr perfex perfusion catheter CH12; B. Braun Medical, Oss, The 
Netherlands) were cannulated and connected to a heart-lung machine which consisted 
of two independent roller pumps (model 10-30-00; Cobe/Stöckert, Munich, Germany). 
The inferior vena cava (IVC) was cross-clamped above the hepatic veins and cannulated 
proximal of the renal veins (Polystan 36 Fr, straight, A/S, Värlöse, Denmark) to allow 
undisturbed blood fl ow from the hepatic veins through the IVC towards the heart-lung 
machine. To isolate the hepatic circuit, tourniquets were secured around the hepatic 
artery, portal vein and IVC.
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For the extracorporeal venovenous bypass, the right femoral vein (22-Fr cannula DI-
ITF022L; Edwards Lifesciences, Irvine, California, USA) and the portal vein (17-Fr perfex 
perfusion catheter CH17; B. Braun) (proximal to the tourniquet) were cannulated and 
connected to the right axillary vein (18-Fr 7326 perfusion cannula; Lifestream Inter-
national, The Woodlands, Texas, USA). The venovenous bypass was supported by a 
centrifugal pump (Medtronic BIO-Medicus, Eden Prairie, Minnesota, USA) and primed 
with 700 mL 0.9 % saline. The perfusion medium consisted of intrahepatically trapped 
blood and 1250 mL Gelofusine® (Vifor Medical, Sempach, Switzerland) plus 2500 units 
heparin (Leo Pharma, Breda, The Netherlands) to yield a fi nal volume of approximately 2 
litres. Throughout the 1-h perfusion interval, the perfusate was kept at a temperature of 
39·5 °C by a heat exchanger and oxygenated using an oxygenator (Cobe VPCML; Cobe 
Cardiovascular, Arvada, Colorado, USA) except for the last patient who was oxygenated 
using a diff erent oxygenator (Dideco D901, SORIN group Italia, Mirandola, Italy). After 
perfusion, the liver was fl ushed for approximately 10 minutes with 3 liters Gelofusine®. 
All cannulas and clamps were removed, and the incisions were closed. To prevent pos-
sible postoperative cholecystitis, cholecystectomy was performed.
Melphalan
Melphalan 200mg (Alkeran®, GlaxoSmithKline, Zeist, The Netherlands) was fi rst dissolved 
in 40 mL Wellcome Diluent (a 60/40 (v/v) mixture of proylene glycol containing 5.2% 
Figure 1. Isolated hepatic perfusion circuit with infusion of melphalan in the hepatic artery (HI-HPP).
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(v/v) ethanol and 0·068 mol/l sodium citrate), which was subsequently diluted with 60 
mL sterile saline. Melphalan was administered through 20 minute infusion using an 
infusionpump (Pilote Anesthesie; Fresenius, Brezins, France) connected to the hepatic 
artery line of the isolated hepatic circuit.
Leakage Detection
Leakage of perfusate into the systemic circuit was monitored by adding 10 MBq 99mTc-
pertechnetate to the isolated circuit with subsequent measurement of the level of 
radioactivity in both the systemic and isolated circuit, as described previously 21, 22. If 
no leakage was detected, melphalan was administered; however, if leakage exceeded 
10% during the perfusion period, the procedure was immediately aborted and the liver 
fl ushed.
Postoperative Care
All patients received a daily subcutaneous dose of 480 μg granulocyte colony-stimulat-
ing factor (G-CSF) (Filgrastim/Neupogen®; Amgen, Breda, The Netherlands) starting the 
day after the operation until the nadir in leukocyte count was reached and the count 
had risen to more than 1.0 × 109/L. Patients were monitored in the intensive care unit 
for at least 1 day after IHP. Liver and renal function tests and full blood counts were 
carried out daily in the fi rst week and henceforth as indicated by their respective levels. 
Antibiotics in a combination of cefuroxim and metronidazol were given to all patients 
for 5 days after IHP.
Toxicity
Systemic and regional toxicity were graded according to the National Cancer Institute 
Common Toxicicity Criteria version 2.0. Hepatic toxicities were considered melphalan re-
lated if elevations in liver function persisted beyond 7 days after perfusion, as previously 
suggested 18. Nonhepatic toxicities were defi ned as all toxicities that are not reversed 
within 24 hours after perfusion.
Melphalan levels
Heparinized samples of four patients were taken from the perfusion medium at the 
infl ow of the hepatic artery and at the outfl ow of the inferior caval vein, at 10 diff erent 
time intervals (t=0, 5, 10, 15, 20, 25, 30, 40, 50, 60 minutes). Samples were stored at -80 oC 
until analysis. All samples were analyzed by a HPLC assay as previously described 23. The 
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areas under the concentration-time curves (AUC) were calculated with the trapezoidal 
rule.
Response evaluation
Objective tumour response measurements were obtained by follow up CT scans of 
the liver and remaining abdomen at 3-month intervals after treatment and at 6-month 
interval after 1 year. Additional imaging was performed if clinically indicated. Both WHO 
and RECIST criteria were used to determine response rates. Hepatic response and overall 
response were measured separately, in view of the local nature of the treatment. Ac-
cording to the WHO criteria the size of all measurable lesions was determined, complete 
response was defi ned as disappearance of all known disease, partial response as a 
reduction in the sum of the product of maximal diameter x longest perpendicular diam-
eter of all measurable metastases of ≥50%, stable disease as a reduction of <50% or an 
increase of <25% and progressive disease as an increase of ≥25% or the appearance of 
new intra- or extrahepatic lesions 24. For the RECIST criteria lesions were only considered 
measurable if ≥10mm, complete response was defi ned as disappearance of all known 
disease, partial response as a reduction in the sum of maximal diameters of ≥30%, stable 
disease as a reduction of <30% or an increase of <20% and progressive disease as an 
increase of ≥20% or the appearance of new intra- or extrahepatic lesions 25. Metastases 
were localized according to the Bismuth classifi cation 26.
Serum carcinoembryonic antigen (CEA) levels were determined prior to treatment and 
at all follow-up visits.
Statistics
All data were analyzed using SPSS (version 12.0) software and presented as mean +/- 
SD or median followed by the range. All survival and disease progression analysis was 
performed by using Kaplan-Meier statistics.
Results
Patient and treatment characteristics
Demographics and tumour characteristics of the patient population are listed in Table 
1. In total, 30 colorectal cancer patients with unresectable liver disease and no evidence 
of extrahepatic disease were treated with HI-HPP: 8 women and 22 men with a mean 
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age of 56 years (range 37 to 69 years). Seventeen patients presented with synchronous 
liver metastases, whereas 13 had metachronous liver metastases. Median time between 
diagnosis of liver metastases and perfusion was 5 months (range 1.5 to 19.8 months). 
Nineteen patients received treatment directed at their liver metastases prior to enrol-
ment in this trial, including systemic chemotherapy in 16 patients, chemoembolization 
in 2 patients and metastasectomy in 1 patient. Seven of the 16 patients who received 
chemotherapy prior to IHP showed progressive disease under therapy. Tumour burden 
varied among patients, the median number of metastatic lesions was 9, but ranged from 
2 to more than 20 lesions. The lesions ranged in size as measured by greatest diameter 
from 2mm to 131mm with a mean diameter of 22mm. The estimated percentage of 
hepatic replacement ranged from 5% to 40% with a mean replacement of 14%. Car-
cinoembryonic antigen (CEA) levels were elevated (> 3.0 μg/mL) in 23 patients prior to 
perfusion.
Treatment parameters are shown in Table 2. All 30 patients underwent HI-HPP. In two 
patients the HI-HPP was prematurely aborted (after 25 and 30 minutes respectively), 
because the calculated maximum tolerated leakage for the entire procedure of 10% 
would be exceeded. Median operative time was 8.8 hours (range 7.0 to 12.8 hours) with 
a median blood and fl uid loss of 4.0 L (range 1.3 to 14.0 L). Median hospital stay was 10 
days (range 7 to 27 days). Mean fl ow rate in the hepatic artery during the 20-minute mel-
phalan infusion was 121.3 mL/min (range 100.0 to 290.0 mL/min) and climbed to 270.7 
mL/min (range 100.0 to 400.0 mL/min) after melphalan administration. Corresponding 
pressures in the hepatic artery during infusion ranged from 33.0 to 140.0 mm Hg (mean 
Table 1 Patient and tumor characteristics
Characteristic n
No. of patients 30
Sex ratio (F:M) 8 : 22
Mean age (years), [range] 55 [36-67]
Liver metastases
synchronous : metachronous 17 :13
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63.5 mm Hg) rising to 40.0 to 160.0 mm Hg (mean 93.2 mm Hg) after melphalan admin-
istration. Actual leakage ranged between 0 and 7.0%.
Toxicity and complications
One patient died perioperatively as a result of a progressive liver failure. Major com-
plications are listed in Table 3. Veno-occlusive disease occurred in 4 patients, while 2 
other patients showed clear signs of portal hypertension not present prior to therapy, 
including oesophageal varices on post-perfusion imaging. One of these patients died 11 
months after perfusion of massive hematemesis. Despite limited leakage and postop-
erative administration of G-CSF, 3 patients developed a grade 3-4 leukopenia. Regional 
toxicity data are presented in Table 4. Grade 4 hepatoxicity was present in 5 patients and 
consisted of elevated levels of bilirubin in 1 patient, elevated transaminases in 1 patient, 
elevated gammaglutamyl transpeptidase in 2 patients and both elevated gammaglu-
tamyl transpeptidase and bilirubin in another patient. The hepatotoxicity was transient 
in most patients, although some elevation persisted in the patients with either VOD or 
portal hypertension.







fl ow rate hepatic artery (mL/min) 121 ± 41 270 ± 95
fl ow rate portal vein (mL/min) 246 ± 56 253 ± 52
pressure hepatic artery (mm/Hg)  64 ± 32  93 ± 30
pressure portal vein
(mm/Hg)
 34 ± 8  35 ± 8
Mean % leakage during perfusion 
(range)
1.2 (0-7)
Values are mean ± s.d.
Table 3 Number of patients with major complications
Major complications HI-HPP
Toxic hepatitis 1
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Melphalan pharmacokinetics
Figure 2 shows a typical example of a drug concentration-versus-time curve of HI-HPP. 
During the 20-minute infusion the melphalan concentration rapidly increases to remain 
at a constant high level (peak concentration of 93.2μg/mL) for approximately 18 minutes. 
The melphalan concentration gradually increases during the fi rst 20 minutes as a result 
of recirculation. After the end of the infusion the melphalan concentration declines 
rapidly to approximately 30 μg/mL followed by a gradual elimination of melphalan.
Table 4 Toxicity according to National Cancer Institute Common Toxicity Criteria (n=30)
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Leukocyte nadir 20 3 4 1 2
Bilirubin 13 6 6 3 2
Alkaline phosphatase 0 7 16 7 0
GGT 0 1 8 18 3
ALAT 2 10 11 6 1
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Figure 2. A typical example of a concentration-time curve of melphalan in perfusate during HI-HPP. A 
constant high level of melphalan is maintained for up to 20 minutes. The peak concentration of 93.2μg/
mL is achieved after 20 minutes. The area under the concentration-versus-time curve (AUC) was calculated 
for the entire procedure: 2841,6 μg x min/mL.
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Tumour response and patient survival
The median follow up time was 44.6 months (range 18.5 to 55.3 months). Nineteen 
patients of the 23 patients with previously elevated CEA levels experienced a normaliza-
tion or reduction of 50% or more 1 to 3 months after perfusion with a median duration 
of response of 4.4 months (range 1.5 to 18.5 months).
Hepatic and overall treatment responses were measured by comparing follow-up CT 
scans to the pre-treatment scan, according to both WHO and RECIST criteria. As 1 patient 
died postoperatively, 29 patients were eligible for measurement of tumour response. 
Twelve patients showed hepatic response according to WHO criteria, as compared to 
15 patients according to the RECIST criteria, with no complete responses. Nine patients 
showed stable disease according to the WHO criteria, while 6 patients showed stable 
disease according to the RECIST criteria. Eight patients immediately showed progressive 
disease for both criteria on the fi rst follow up CT scan. The median duration of hepatic 
response (partial remission) was 11.5 months (range 4.4 to 48.6 months) for WHO criteria 
and 9.1 months (range 5.2 to 48.6 months) for RECIST criteria. In 3 patients hepatic pro-
gression has not occurred at respectively 18.5, 36.3 and 48.6 months. Two patients with 
hepatic stable disease and 1 patient with hepatic partial remission, according to WHO 
criteria, showed extrahepatic disease on the fi rst follow up scan, resulting in an overall 
response in 11 patients. For the RECIST criteria, 2 patients with hepatic partial remis-
sions and 1 patient with stable disease, showed extrahepatic disease on the fi rst follow 
up scan, resulting in an overall response 13 patients. The time to overall progression 
(hepatic and/or extrahepatic) and overall survival curves are shown in fi gure 3. Progres-
sion occurred in 27 of the 29 patients, 15 of these patients showed hepatic progression, 
5 patients extrahepatic and 7 patients had both hepatic and extrahepatic progression. 
In retrospect, two patients with extrahepatic progression had extrahepatic disease pre-
operatively. Median time to progression (hepatic and/or extrahepatic) was 6.6 months 
(range 1.4 to 43.7 months) for both WHO and RECIST criteria. The median overall survival 
after perfusion was 16. 9 months (range 0.9 to 52.5 months) with 7 patients still alive. The 
median overall survival after diagnosis of liver metastases was 27.8 months (range 5.2 to 
64.6 months). Twenty-one patients received therapy after perfusion, including adjuvant 
systemic treatment in 1 patient, systemic treatment for metastatic disease in 19 patients 
and metastasectomy of pulmonary metastases in 1 patient.
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Discussion
Isolated hepatic perfusion is based on the principle of high regional drug exposure with 
limited systemic toxicity. By means of a 20 minute hepatic artery infusion of 200mg 
melphalan followed by a 40 minutes perfusion, we wanted to achieve a selective tumour 
exposure to an increased concentration of melphalan, as compared to conventional 
perfusion circuits with a drug bolus administration. Previous studies have shown a rapid 
decline of melphalan in the perfusate, as measured 5 tot 15 minutes after bolus admin-
istration with mean peak concentrations ranging between 18.1 to 38.6 μg/mL 17, 27. This 
study in 30 colorectal cancer patients demonstrated that HI-HPP with 200mg melphalan 
results in high local concentrations of melphalan, with a maximum peak concentration 
of 93.2μg/mL, for up to 20 minutes. However, toxicity was considerable and increased 
selective drug exposure did not improve response rates and survival compared to previ-
ous studies 18, 27.
Figure 3. Overall and progression free (hepatic and/or extrahepatic) survival curves for WHO and RECIST 
criteria after HI-HPP. For the survival analysis all 30 patients were included. For the progression free 
survival (both RECIST and WHO) 29 patients were evaluable, as 1 patient died perioperatively. At a median 
follow up of 44.6 months 11 patients remain alive and progression has not occurred in 2 patients.
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Veno-occlusive disease (VOD) was present in 4 patients, while 2 other patients developed 
portal hypertension, possibly as a result of VOD. Several other studies have reported 
cases of VOD after IHP, but only incidentally 18, 27-29. A phase II trial at our institution with 
bolus administration of the same dose of melphalan resulted in VOD, only in 4 out of 71 
patients 16. VOD is thought to result from accumulative exposure to chemotherapeutic 
agents, but the patients in this study were exposed to similar amounts of chemotherapy 
as compared to previous studies 30. A similar trend was observed in grade 4 biliairy toxic-
ity, which occurred in as many as 5 out of 30 patients and 1 patient died of progressive 
liver failure. The toxicity data from this clinical study are in line with the results of an 
animal study, previously performed at our institution. In an in vivo rat model for liver 
tumours we studied the diff erence in tumour and liver uptake as well as an antitumour 
eff ect and hepatotoxicity of 5 and 20 minute arterial infusion of a fi xed melphalan dose 
31. No diff erence in melphalan content of tumour/liver tissue and tumour response 
was found between the two infusion schedules. Hepatoxicity, on the other hand, was 
strongly aff ected by infusion duration and hence melphalan concentration. Severe 
cholangiofi brosis occurred in 8 of 9 rats treated with 5 minute infusion, but in only 1 of 
8 rats treated with a 20 minute infusion, hence we considered a 20 minute infusion in 
humans to be safe. Liver toxicity appears to have a steep concentration-toxicity curve, 
independent of the total dose of melphalan
This study shows a hepatic response rate of 40% (according to WHO criteria) with a 
median duration of hepatic response of 11.5 months. Bartlett et al reported the results 
of IHP with 1.5mg/kg melphalan in 51 colorectal cancer and 1mg TNF-α in a subset of 
32 patients, with a local response rate of 76% with a median duration of 10.5 months 27, 
similar to our own experience 16. Contrary to toxicity, response seems to be determined 
by the total dose of melphalan, not by melphalan concentration levels. Although this 
might explain the absence of improved response it does not explain the actual reduc-
tion in response.
One of the major drawbacks of HI-HPP is the low pressure and fl ow in the perfusion 
circuit. In a regular IHP setup mean fl ow rates ranging between 502 to 844 mL/min and 
associated pressures of 159 to 164 mm Hg can be achieved 17, 18. In this study we achieved 
a mean fl ow rate of 121.3 mL/min (mean pressure 63.5 mm Hg) during infusion and 
270.0 mL/min (mean pressure 93.17 mm Hg) during perfusion. Effi  cacy of chemothera-
peutic agents in the treatment of solid tumours is, on top of the development of drug 
resistance of cancer cells, dependent upon the drug delivery and penetration within the 
tumour. Impaired transport of cytostatic agents into the tumour has been attributed to 
changes in the extracellular matrix, deformed tumour vasculature and pathologically 
increased interstitial fl uid pressure (IFP) 32-34. Less et al measured the IFP in colorectal 
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liver metastases and found a mean IFP of 10 times above the IFP of normal liver tissue 
35. In animal models, lowering of the IFP, through for example prostaglandin E1 (PGE1), 
resulted in an improved drug penetration 36, 37. It has even been argued that the increase 
in disease-free survival seen in phase III trials of conventional chemotherapy combined 
with a monoclonal antibody against vascular endothelial growth factor, is partly at-
tributable to the IFP lowering eff ect of bevacizumab 38. It seems likely that a reduction 
of more than 50% in fl ow rate and pressure during perfusion would lead to decreased 
melphalan penetration and hence tumour response. Healthy liver and biliary tract tis-
sue, on the other hand, with a normal IFP is penetrated by the melphalan, resulting 
in the previously described toxicity. Ideally, decreased penetration of melphalan in the 
tumour is determined by detecting melphalan levels in liver biopsies taken during and 
after perfusion. However, in our experience this would increase morbidity considerably 
due to haemorrhage as a result of heparinization.
The current IHP technique is an expensive, demanding and technically diffi  cult proce-
dure with considerable morbidity and mortality, which is not amenable to repetition, 
therefore attention has shifted to the development of a less complicated percutaneous 
technique. Several phase I studies, using a variety of percutaneous approaches with 
variable results, have been published so far 39, 40. Savier et al reported treatment of 4 
patients with 3 successive courses of chemotherapy by IHP, in which the fi rst course 
was given at laparotomy and the next two courses percutaneously 29. Percutaneous 
isolation of the liver was achieved by placing an occlusion catheter in the portal vein 
according to the transhepatic Seldinger technique and a double-balloon catheter in the 
retrohepatic caval vein through the saphenous vein. Finally, the HA was occluded by 
traction of a silicon-lined nylon thread that was positioned around the common hepatic 
artery during previous laparotomy. Although isolated perfusion was achieved by this 
method, considerable leakage to the systemic circulation occurred during IHP and 
the fl ow rate was limited to 200-300mL/min. Phase II trials need to be performed for a 
sensible determination of response rates. Nevertheless, in view of our fi ndings response 
rates could be disappointing, considering the limited fl ow rate due to catheter size in a 
percutaneous technique.
In summary, we have demonstrated that HI-HPP with 200mg melphalan results in high 
perfusate melphalan concentration levels, but is associated with a relatively high level 
of hepatotoxicity and a limited response rate. We believe that the low fl ow rates and 
pressures found in this study can result in reduced drug penetration of the tumour and 
thus limited tumour response. This could prove to be an important consideration in the 
development of future percutaneaous isolated hepatic perfusion techniques. We will 
abandon HI-HPP and are currently focusing on the introduction of new tumour-specifi c 
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agents in an isolated hepatic perfusion system capable of producing adequate fl ow and 
pressure rates.
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Abstract
The aim of this study was to identify prognostic factors for local and systemic failure 
after isolated hepatic perfusion (IHP) with 200 mg melphalan in patients with colorectal 
liver metastases.
Hundredandfi fty-four patients were selected for IHP and underwent laparotomy. Patients 
were monitored for response, toxicity and survival. Univariate and multivariate analyses 
were performed to identify prognostic factors for hepatic response, progression-free 
and overall survival.
Hepatic response rate was 50% with a median progression free and overall survival 
of respectively 7.4 months and 24.8 months. In multivariate analyses, absence of abil-
ity to perfuse through the hepatic artery (P=.003), severe postoperative complications 
(P=.048) and more than 10 liver metastases (P=.006) adversely infl uenced overall survival 
and no adjuvant chemotherapy adversely infl uenced progression-free survival.
This is the fi rst study to report prognostic factors for survival after IHP. Possibly, overall 
and disease-free survival can increase if preoperative screening is improved. In future 
studies on IHP, adjuvant chemotherapy should be considered.
Liselot BW.indd   58 25-10-11   11:59
Chapter 4: IHP of liver metastases outcome and prognostic factors in 154 patients
59
Introduction
In approximately 30% of colorectal cancer patients the liver is the only site of metastatic 
disease 1, 2. Complete surgical resection is considered the treatment of choice with 5-year 
survival rates ranging from 25-51%. However metastasectomy is only possible in less 
than 10 percent of patients due to the number, location or size of the metastases 3-5. The 
management of irresectable colorectal liver metastases remains a challenge for both 
medical oncologists and surgeons. Recent studies have shown improved survival with 
the introduction of oxaliplatin, irinotecan, bevacizumab and cetuximab in the systemic 
treatment of colorectal metastases 6-11. Regional treatment options however, can off er 
the potential benefi t of both aggressive local treatment and limited systemic toxicity. 
Several regional therapies have been developed including radiofrequency ablation 
(RFA) and isolated hepatic perfusion (IHP). Phase II studies involving IHP in colorectal 
cancer patients have shown hepatic response rates up to 74% with a median time to 
hepatic progression up to 14.5 months, a median overall survival of 27 months and 5 
year survival of 9%, establishing its value in the treatment of colorectal liver metasta-
ses12-15. While several studies have been published on prognostic factors in RFA, little is 
known about prognostic factors in IHP16, 17. Most IHP studies focus on local response rate 
and recurrence, but the at least equally important systemic (i.e. extrahepatic) failure is 
scarcely reported. The aim of this study was to evaluate both local and systemic failure 




In the 10-year period from August 1994 and December 2004, 179 patients with liver 
metastases were considered for treatment with 200mg melphalan, according to a study 
protocol approved by the medical ethical committee of the Leiden University Medical 
Center, as previously published 12, 18. The data were obtained from a prospectively col-
lected database and analyzed retrospectively. In 25 patients the primary tumor was of 
non-colorectal origin and these patients were excluded, leaving 154 patients for further 
analysis. Informed consent was obtained from all patients. All patients had measurable, 
irresectable colorectal metastases confi ned to the liver. Standard staging studies were 
performed including CT scan of the chest and abdomen. Additional MRI or PET scans 
were performed if clinically indicated. Eligibility criteria included a WHO performance 
status of 0 or 1, leukocyte count ≥ 3.0 × 109/L, platelet count ≥ 100 × 109/L, maximum 
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serum creatinine level 135 μmol/L, maximum bilirubin level 17 μmol/L and minimum 
albumin level 40 g/L. Exclusion criteria were age over 70 years, life expectancy of less 
than 4 months, more than 60 percent hepatic involvement of tumour tissue as estimated 
from the preoperative abdominal CT scan, coagulation disorders and evidence of ex-
trahepatic metastatic disease. The interval between resection of the primary colorectal 
tumour and perfusion had to be at least 6 weeks.
IHP technique
Briefl y, the liver was mobilized from the diaphragm through a transverse abdominal 
incision. The common hepatic artery (8-Fr 77008 one-piece pediatric arterial cannula; 
Medtronic, Minneapolis, Minnesota, USA) and the portal vein (12-Fr perfex perfusion 
catheter CH12; B. Braun Medical, Oss, The Netherlands) were cannulated and connected 
to a heart-lung machine which consisted of two independent roller pumps (model 
10-30-00; Cobe/Stöckert, Munich, Germany). The inferior vena cava (IVC) was cross-
clamped above the hepatic veins and cannulated proximal of the renal veins (Polystan 
36 Fr, straight, A/S, Värlöse, Denmark) to allow undisturbed blood fl ow from the hepatic 
veins through the IVC towards the heart-lung machine. To isolate the hepatic circuit, 
tourniquets were secured around the hepatic artery, portal vein and IVC.
For the extracorporeal venovenous bypass, the right femoral vein (22-Fr cannula DI-
ITF022L; Edwards Lifesciences, Irvine, California, USA) and the portal vein (17-Fr perfex 
perfusion catheter CH17; B. Braun) (proximal to the tourniquet) were cannulated and 
connected to the right axillary vein (18-Fr 7326 perfusion cannula; Lifestream Inter-
national, The Woodlands, Texas, USA). The venovenous bypass was supported by a 
centrifugal pump (Medtronic BIO-Medicus, Eden Prairie, Minnesota, USA) and primed 
with 700 mL 0.9 % saline. The perfusion medium consisted of intrahepatically trapped 
blood and 1250 mL Gelofusine® (Vifor Medical, Sempach, Switzerland) plus 2500 units 
heparin (Leo Pharma, Breda, The Netherlands) to yield a fi nal volume of approximately 2 
liters. Throughout the 1-h perfusion interval, the perfusate was kept at a temperature of 
39·5 °C by a heat exchanger and oxygenated using an oxygenator (Cobe VPCML; Cobe 
Cardiovascular, Arvada, Colorado, USA) except for the last patient who was oxygenated 
using a diff erent oxygenator (Dideco D901, SORIN group Italia, Mirandola, Italy). After 
perfusion, the liver was fl ushed for approximately 10 minutes with 3 liters Gelofusine®. 
All cannulas and clamps were removed, and the incisions were closed. To prevent pos-
sible postoperative cholecystitis, cholecystectomy was performed.
Liselot BW.indd   60 25-10-11   11:59
Chapter 4: IHP of liver metastases outcome and prognostic factors in 154 patients
61
Melphalan
Melphalan 200mg (Alkeran®, GlaxoSmithKline, Zeist, The Netherlands) was fi rst dissolved 
in 40 mL Wellcome Diluent (a 60/40 (v/v) mixture of proylene glycol containing 5.2% 
(v/v) ethanol and 0·068 mol/l sodium citrate), which was subsequently diluted with 60 
mL sterile saline. Melphalan was administered as a bolus in the isolated hepatic circuit 
and in the last 30 patients through 20 minute infusion using an infusionpump (Pilote 
Anesthesie; Fresenius, Brezins, France) connected to the hepatic artery line of the iso-
lated hepatic circuit.
Leakage Detection
Leakage of perfusate into the systemic circuit was monitored by adding 10 MBq 99mTc-
pertechnetate to the isolated circuit with subsequent measurement of the level of 
radioactivity in both the systemic and isolated circuit, as described previously 19, 20. If no 
leakage was detected, melphalan was administered; if leakage was calculated to exceed 
10% during the perfusion period, the procedure was stopped and the liver was fl ushed 
just before this level was reached.
Postoperative Care
All patients received a daily subcutaneous dose of 480 μg granulocyte colony-stimulat-
ing factor (G-CSF) (Filgrastim/Neupogen®; Amgen, Breda, The Netherlands) starting the 
day after the operation until the nadir in leukocyte count was reached and the count 
had risen to more than 1.0 × 109/L. Patients were monitored in the intensive care unit 
for at least 1 day after IHP. Liver and renal function tests and full blood counts were 
carried out daily in the fi rst week and henceforth as indicated by their respective levels. 
Antibiotics in a combination of cefuroxim and metronidazol were given to all patients 
for 5 days after IHP.
Toxicity
Systemic and regional toxicity were graded according to the National Cancer Institute 
Common Toxicity Criteria version 2.0. Hepatic toxicities were considered melphalan 
related, if elevations in liver function persisted beyond 7 days after perfusion, as previ-
ously suggested 13.
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Response evaluation
Objective tumour response measurements were obtained by follow up CT scans of the 
liver and remaining abdomen at 3-month intervals after treatment and at 6-month in-
tervals after 1 year. Additional imaging was performed if clinically indicated. All CT scans 
were reviewed using RECIST criteria to determine response rates. According to RECIST 
criteria lesions were only considered measurable if ≥10mm, complete response was 
defi ned as disappearance of all known disease, partial response as a reduction in the 
sum of maximal diameters of measurable lesions of ≥30%, stable disease as a reduction 
of <30% or an increase of <20% and progressive disease as an increase of ≥20% or the 
appearance of new intra- or extrahepatic lesions 21. Disease-free survival was calculated 
from the date of IHP until the date of local and/or systemic recurrence or death from any 
cause.
Serum carcinoembryonic antigen (CEA) levels were determined prior to treatment and 
at all follow-up visits.
Statistics
All data were analyzed using SPSS (version 14.0) software and presented as mean +/- 
SD or median followed by the range. Survival was measured from the day of surgery 
until death or until the last day of follow up. Postoperative mortality was included in 
the response and survival analysis. For discrete variables univariate analysis was per-
formed with the χ2 test. Factors with P < 0.10 in univariate analysis were entered in the 
multivariate analysis using logistic regression. Odds ratios are reported with 95 percent 
confi dence intervals. Overall survival and disease progression analysis was analyzed 
using Kaplan-Meier curves, the log-rank test was used to identify diff erences in survival 
between groups. Factors with P < 0.10 in univariate analysis were entered in the multi-
variate analysis using Cox’s proportional hazards model. Hazard ratios are shown with 95 
percent confi dence intervals. All reported P values are two sided.
Results
Patient and treatment characteristics
Of the total of 154 colorectal cancer patients with unresectable liver metastases con-
sidered suitable for IHP, 105 (68%) were actually treated with IHP. At surgery 34 patients 
showed signs of extrahepatic disease not detected previously on imaging, 8 patients 
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showed more than 60 percent hepatic involvement of tumour tissue, 2 patients could 
not be treated due to a vascular anomaly and in 5 patients an isolated circuit could not 
be achieved due to excessive hemorrhage. After a median follow up of 85.4 months this 
group non-IHP patients showed a median overall survival of 10.1 months (range 1.6 – 66.2 
months). They were excluded from further analysis. Demographics and tumour charac-
teristics of the patients treated with IHP are listed in Table 1. Treatment parameters are 
Table 1 Patient and tumour characteristics
Characteristic n (%)




























Localization of primary tumour
Right sided colon










Median duration from diagnosis of liver metastases to 
IHP (months), [range]
4.8 [0.9-34.4]
Prior treatment directed at liver metastases
Chemotherapy a
 Single agent 5FU based regimens
 Oxaliplatin based regiments







a In total 56 lines of chemotherapy were given to a total of 51 patients.
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shown in Table 2. In 10 patients the perfusion did not take place for the full 60 minutes 
due to leakage. Two patients were perfused for 50 minutes, 1 for 45 minutes, 4 for 30 
minutes, 1 for 25 minutes and two for 10 minutes. Between August 1997 and December 
2000 patients received standard advice to undergo adjuvant systemic treatment, which 
at that time was standard protocol for all local treatments of liver metastases at our 
center. Whether patients did actually undergo adjuvant systemic treatment depended 
upon patient wishes and if referred to other centers, local policy. Seventeen (16%) 
patients received adjuvant chemotherapy after IHP. Fourteen patients received 5-FU/
leucovorin based schedules, 2 patients received raltitrexed, while 1 patient was treated 
with irinotecan. Median follow up was 85.4 months (range 21.9 to 147.7 months).
Toxicity and complications
Six patients died within 30 days after IHP because of progressive liver failure and multi-
organ failure and 1 more patient died 3 months after IHP due to a liver abscess, resulting 
in an operative mortality of 7%. Major complications are listed in Table 2. Systemic toxici-
ties are listed in Table 3. Grade 3 or 4 hepatotoxicity was present in 41 (39%) patients. 
Table 2 Treatment parameters
Parameter Mean ± SD n (%)
Perfusion





Flow rate hepatic artery (mL/min) 337 ± 103
Flow rate portal vein (mL/min) 294 ± 92
pressure hepatic artery (mm/Hg) 105 ± 31
pressure portal vein(mm/Hg) 33 ± 9
Percentage leakage during perfusion 1.6 ± 2.3
Blood loss (L) 5.7 ± 4.2
Operative time (hr) 9.5 ± 1.5
Hospital stay (days) 13 ± 7
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Sixteen (15%) patients experienced more than one grade 3 or 4 hepatotoxicity. Although 
some elevation persisted in the patients with either VOD or portal hypertension, the 
hepatotoxicity was transient in most patients. There was no signifi cant diff erence in 
grade 3 or 4 hepatotoxicity between patients with or without chemotherapeutic prior 
to IHP (449% v 56%; P=0.44).
Tumour response
Seventy-two (81%) of the 89 patients with previously elevated CEA levels experienced a 
normalization or reduction of 50% or more 1 to 3 months after perfusion with a median 
duration of response of 6.3 months (range 1.6 to 107.8 months).
Hepatic and overall treatment responses were measured by comparing follow-up CT 
scans to the pretreatment scan, according to RECIST criteria. As 7 patients died postop-
eratively and 1 patient died within 3 months of progressive bone metastases, 97 patients 
were eligible for measurement of tumour response. Hepatic response rate (complete 
and partial remission) was 50% (N=52/105) including 3 complete responses. Twenty-
three patients (22%) had stable disease, whereas 22 patients (21%) immediately showed 
progressive disease. The median duration of hepatic response (complete and partial 
remission) was 11.4 months (range 5.2 to 108 months). Table 4 shows the results of 
univariate analysis for prognostic factors of hepatic response (complete or partial remis-
sion). Univariate analysis revealed that positive prognostic factors for hepatic response 
to IHP were female sex and adjuvant chemotherapy. Multivariate analysis confi rmed the 
positive eff ect of adjuvant chemotherapy (odds ratio for complete or partial remission, 
5.91; 95% CI, 1.54 to 22.6; P=.009), the eff ect of female sex was borderline signifi cant 
(odds ratio for complete or partial remission, 2.65; 95% CI, 0.98 to 7.15; P=.05).
Table 3 Toxicity according to National Cancer Institute Common Toxicity Criteria version 2.0 (n=105)
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Local and systemic failure
One patient died 8 months after IHP of progressive cholestatis before progression oc-
curred. As seven patients died postoperatively, 97 patients were available for response 
evaluation. All patients, except 4, showed progressive disease during follow up. The 
Table 4 Prognostic factors evaluated in univariate analysis in this study
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Factors with P < 0.10 in univariate analysis were entered in the multivariate analysis using logistic 
regression.
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median progression-free survival was 7.4 months (range 1.4 to 107.8 months). Of the 
progressive patients, 63 (68%) showed hepatic progression, 13 (14%) extrahepatic 
progression and 17 (18%) a combination of both hepatic and extrahepatic progression. 
Of the hepatic progressive patients, 14 (17%) showed new hepatic lesions, 27 (34%) 
showed an increase of preexistent hepatic lesions and 39 (49%) showed a combination 
of both. Extrahepatic progression occurred mainly in the lungs (43%), intra-abdominal 
lymph nodes (27%) and cerebrum (10%). Other locations included bones, mediastinal 
lymph nodes and abdominal wall. In retrospect 7 (7%) patients showed extrahepatic 
disease prior to IHP. Univariate analysis revealed that positive prognostic factors for pro-
gression-free survival were: no chemotherapy prior to IHP and adjuvant chemotherapy 
following IHP (P=.09 and P=.01, respectively; Table 4). Median progression-free survival 
was 13.6 months in the patients who received adjuvant chemotherapy, as compared to 
6.8 months in the patients who were not treated with adjuvant chemotherapy (Figure 1). 
Cox multivariate analysis confi rmed a statistically signifi cant positive eff ect of adjuvant 
chemotherapy on progression-free survival (P=.039; Table 5)
Overall survival
Ten patients were still alive at the end of follow up. Seventy-nine (75%) patients received 
treatment directed at their metastases after progression following IHP. In total 73 (70%) 
























Fig 1. Progression-free survival after IHP with and without adjuvant chemotherapy. As patients were not 
randomized for adjuvant treatment, the diff erence, although remarkable could be due to selection bias.
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patients received cytostatic treatment. Three patients underwent a combined resection 
and ablation of their metastases, 6 patients received ablative treatment for their liver 
metastases, 4 patients underwent a hepatic resection and in 1 patient lung metastases 
were resected. The median overall survival was 24.8 months (range 0.3 to 108 months) 
with an observed 3-year and 5-year survival rate of 26% and 8% respectively. Patients 
with a complete or partial hepatic response to IHP showed a median overall survival of 
32.7 months, as compared to 16.2 months for the non-responders (P<.0001). The median 
survival since diagnosis of hepatic metastases was 31.8 months (range 1.83 to 110.7 
months). Univariate analysis revealed a negative eff ect of increasing age and limited 
viable liver tissue, but only increasing number of metastases, absence of hepatic artery 
perfusion, postoperative complications and retrospective extrahepatic metastasis prior 
to IHP reached statistical signifi cance (P=.01, P=.002, P=.03 and P=.008, respectively; 
Table 4). Risk of death by Cox proportional hazards model was 1.5 for patients of 60 years 
and older, 1.9 for 10 or more liver metastases, 4 for absence of hepatic artery perfusion, 
1.6 for the presence of postoperative complications and 2.2 for extrahepatic metastases 
prior to IHP (P=.058, P=.006, P=.002, P=.048 and P=.059, respectively; Table 6).
Discussion
This study reports the results of IHP with 200 mg melphalan in 105 colorectal cancer 
patients. Hepatic response rate was 50% with a median progression free survival of 
7.4 months and a median overall survival of 24.8 months. Although these results are 
promising little is known about the appropriate timing of IHP in the treatment of liver 
metastases of colorectal cancer patients and whether in this selected group of patients 
similar results could be achieved with systemic therapy alone. Recently Alexander et al 
showed IHP with melphalan to be safe and effi  cacious after irinotecan-based therapy 14. 
In 25 patients progressive after irinotecan-based therapy the median time to progres-
sion after IHP was 5 months, while the median overall survival was 12 months. In our 
study 51 patients received chemotherapy prior to IHP, mainly 5FU-based monotherapy 
schedules, with some patients having received either irinotecan or oxaliplatin. Hepa-
Table 5 Multivariate Cox proportional hazards model for progression-free survival
Parameter OR 95%CI P
Chemotherapy directed at liver metastases prior to IHP
No
Yes 1






0.55 0.32 to 0.97
.039
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toxicity and hepatic response rate did not diff er between patients who were pretreated 
with chemotherapy or not, suggesting IHP is an option for both fi rst and second line 
treatment of colorectal liver metastases. The past decade, as our trial was conducted, 
the application of liver resection has widened, by downstaging liver metastases through 
neoadjuvant chemotherapy, further complicating the role and timing of IHP 22. In view 
of the above, diff erent treatment algorithms seem possible, patients could fi rst receive 
systemic treatment to see if downstaging is possible and receive IHP incase of treat-
ment failure. However, patients with a poor response to chemotherapy often show a 
performance status unsuitable for IHP. Therefore, in a selected group of patients, IHP 
could also be considered fi rst line treatment followed by liver resection if downstaging 
occurs. In our study, only 4 patients underwent hepatic resection after IHP, limiting the 
results on effi  cacy and toxicity, warranting further investigation.
The recent increasing success in the development of systemic treatment of colorectal 
cancer patients has caused a shift in interest away from regional treatment options. 
Nevertheless IHP, contrary to systemic treatment, has been shown to result in long-term 
survival with an actual 5-year survival rate of approximately 9% 12. Although regional 
treatments off er the benefi t of limited systemic toxicity, they are often associated with 
operative morbidity and even in some cases mortality. Recent studies show periopera-
tive mortality rates around 5% in IHP 12, 13, 15. Ideally patients should be selected who will 
benefi t most from this procedure. Several studies have focused on the eff ect of age, 
Table 6 Multivariate Cox proportional hazards model for overall survival











1.95 1.21 to 3.12
.006











Hepatic artery and portal vein perfusion
No hepatic artery perfusion
1






1.54 1 to 2.36
.048




2.23 0.97 to 5.11
.059
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tumor size, number of metastases and extrahepatic disease on disease-free and overall 
survival after resection cryoablation and RFA 17, 23-25, while to our knowledge no such 
studies exist concerning IHP. Berber et al examined the prognostic factors after RFA in 135 
colorectal cancer patients 17. They identifi ed number and size of liver metastases, serum 
CEA level as prognostic factors for overall survival in univariate analysis and tumour size 
in multivariate analysis. Thirty-three percent of their patients had extrahepatic disease 
prior to RFA, remarkably this did not eff ect overall survival. In our study we determined 
parameters that identifi ed the patients with superior results after IHP for colorectal 
cancer liver metastases. We found absence of hepatic artery perfusion, postoperative 
complications, number of metastases, age and presence of extrahepatic disease prior to 
IHP as evaluated retrospectively, of prognostic signifi cance for overall survival in univari-
ate analysis. In multivariate analysis only the fi rst three remained statistically signifi cant. 
Although the presence of extrahepatic disease prior to IHP did not reach signifi cance 
(P=.059) for overall survival in multivariate analysis, a clear trend could be observed.
Elias et al reported the results 506 colorectal cancer patients who underwent a 
laparotomy and then a resection for liver metastases 26. Prior to laparotomy CT scan 
and liver ultrasonography were performed. Unsuspected metastases were discovered 
in 209 (41.3%) patients; extrahepatic metastases in 82 (16.2%) patients, additional liver 
metastases in 152 (30%) patients and both in 25 (4.9%) patients.
Patients in our study were subjected to a spiral CT scan of both abdomen and thorax 
prior to enrollment and CT AP. Nevertheless, similarly to the results of Elias et al, 34 
(22%) in our study were found to have extrahepatic disease preoperatively and did not 
undergo IHP. Recently percutaneous IHP procedures have been developed to enable a 
less invasive and repeatable procedure 27, 28. A percutaneous approach would inhibit pre-
operative detection of these extrahepatic metastases and could lead to the unnecessary 
treatment with IHP. The preoperative detection modality of colorectal metastases has 
been the subject of much debate 29-31. Truant et al reported a prospective double-blind 
comparison of FDG-PET and thoracoabdominal CT scan in 53 patients with potentially 
resectable liver metastases from colorectal cancer 31. The sensitivity of PET was equiva-
lent to that of CT (both 79%), but was superior for extrahepatic abdominal sites (63% 
and 25% respectively). PET, on the other hand, falsely upstaged three patients. Selzner et 
al reported the results of a prospective comparison between contrast-enhanced CT scan 
and FDG-PET in 76 colorectal cancer patients evaluated for liver resection 29. CT and PET 
provided comparable sensitivity for the detection of intrahepatic metastases. However, 
extrahepatic disease was missed in one third of the cases using CT (sensitivity 64%), 
while PET failed to detect extrahepatic lesions in only 11% of the cases (sensitivity 89%). 
The introduction of a standard PET scan in our pre-IHP work up would probably reduce 
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the number of patients undergoing unnecessary laparotomies. On the other hand both 
the number of false positive patients and imaging-associated costs would increase 
substantially. Nevertheless, to decrease both the number of patients treated with IHP 
with extrahepatic disease (associated with signifi cantly reduced overall survival) and the 
number of unnecessary laparotomies, preoperative work up needs to be improved. Pos-
sibly a selection of patients with an increased a priori chance of extrahepatic metastases 
should undergo PET-scanning prior to IHP.
Yan et al studied the prognostic factors for progression-free survival in 135 colorectal 
cancer patients treated with cryoablation with or without resection 32. Pre- and post-
operative CEA, size and number of metastases were prognostic factors for progression 
free survival. In our study tumor load as estimated by remaining percentage of viable 
liver tissue and number of metastases did not infl uence progression-free survival. Adju-
vant chemotherapy, on the other hand, did infl uence progression free survival in both 
univariate and multivariate analysis. However, this therapy was not randomized and par-
tially given based on the personal opinion of patients respective medical oncologists. A 
recent meta-analysis of seven randomized controlled trials comparing resection or RFA 
with observation to resection or RFA with adjuvant hepatic artery chemotherapy could 
not detect a survival benefi t for the chemotherapy group 33. Portier et al reported the 
results of a randomized control trial of adjuvant systemic 5FU and folinic acid compared 
with surgery alone after resection of colorectal liver metastases34. In a multicenter trial 
173 patients with R0 resected hepatic metastases were randomly assigned to surgery 
alone or to surgery followed by 6 months of systemic adjuvant chemotherapy with a 
5-fl uorouracil and folinic acid monthly regimen. The 5-year progression-free survival 
rate was 33.5% for patients in the chemotherapy group and 26.7% for the patients in the 
control group (P=.028). A trend towards increased overall survival for the chemotherapy 
group was observed, but did not reach statistical signifi cance. Although our study was 
not designed to compare IHP alone to IHP with adjuvant systemic treatment the dif-
ference in disease-free survival for the 17 patients who received adjuvant treatment 
was remarkable. Nonetheless selection bias can not be excluded, therefore studies with 
adjuvant chemotherapy after IHP should be considered.
In conclusion, the results of this study are encouraging and add to the currently avail-
able data on IHP. This is the fi rst study to identify prognostic factors in patients who are 
treated with IHP. More than 10 liver metastases, absence of the ability to perfuse through 
the hepatic artery and postoperative complications adversely infl uence the overall 
survival, while adjuvant chemotherapy improves the hepatic response and progression-
free survival. An improvement of overall and disease-free survival after IHP is likely if 
preoperative screening is improved and adjuvant chemotherapy is administered.
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Abstract
To compare the median overall survival of patients with isolated non-resectable liver 
metastases in comparable groups of patients treated with either isolated hepatic perfu-
sion (IHP) with melphalan or systemic chemotherapy
All patients with isolated liver metastases from colorectal cancer origin, who underwent 
IHP with 200mg melphalan between August 1994 and December 2004, through both 
the portal vein and hepatic artery, were included in this study. The control group con-
sisted of a subgroup of colorectal cancer patients with liver metastases only, who were 
enrolled in the randomized CApecitabine, IRinotecan, Oxaliplatin (CAIRO) phase III study 
between January 2003 and December 2004.
Ninety-nine patients were treated with IHP, and 111 patients were included in the con-
trol group. All patient characteristics were comparable except for age. Median follow 
up was 78.1 months for IHP versus 54.7 months in the control group. Median overall 
survival was 25.0 (95% CI 19.4-30.6) months for IHP and 21.7 (95% CI 19.6-23.8) months 
for systemic treatment (P=0.29). Overall survival was not infl uenced by gender, age, 
LDH, location of primary tumor, timing of liver metastases and adjuvant treatment of 
the primary tumor and was only infl uenced by metastasectomy after study treatment 
(P<0.001). However, the number of patients in whom metastasectomy was performed 
did not diff er signifi cantly between the two groups. Treatment-related mortality was 2% 
for the systemic treatment and 6% for IHP (P=0.11).
Compared to a patient group with comparable characteristics treated with systemic 
chemotherapy, IHP does not provide a benefi t in overall survival in patients with isolated 
non-resectable colorectal liver metastases. Currently the use of IHP cannot be advocated 
outside the scope of clinical studies.
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Introduction
The treatment of patients with metastatic colorectal cancer is with palliative intent, and 
with standard cytotoxic drugs median overall survival times of approx. 17 months can 
be achieved, which may be further improved by the use of targeted agents 1. Long-term 
survival and sometimes cure may be achieved in the subset of patients in whom a radical 
resection of metastases can be performed. The liver is the only site of metastatic disease 
in approximately 30% of colorectal cancer patients 2, 3. Although complete surgical 
resection is considered the treatment of choice, with 5-year survival rates ranging from 
25-51%, metastasectomy is only possible in less than 10 percent of patients, due to the 
number, location or size of the metastases 4-6. The treatment of non-resectable colorectal 
liver metastases remains a challenge for both medical oncologists and surgeons. Down-
sizing of metastases by chemotherapy may allow secondary resections in a minority of 
patients, but the clinical benefi t is uncertain due to the lack of prospective randomized 
studies 1. Regional cytotoxic treatment options can off er the potential benefi t of both 
aggressive local treatment and limited systemic toxicity. Phase II studies involving iso-
lated hepatic perfusion (IHP) in colorectal cancer patients have shown hepatic response 
rates up to 74% with a median time to hepatic progression up to 14.5 months, a median 
overall survival of 27 months and 5 year survival of 9%7-11. Currently, new techniques 
and agents are applied to further improve the results of IHP 12, 13.Although these results 
seem promising, so far the defi nite role of IHP has not been established. Possibly, in this 
selected group of patients, similar results can be achieved with systemic therapy alone. 
Since a randomized controlled trial comparing IHP, a complex surgical procedure with 
considerable mortality, with systemic treatment appears not feasible as well as possibly 
unethical, we performed a case-control study. In this study, we compared the overall 
survival after IHP treatment and systemic treatment in comparable patient groups. 
Our results on IHP were obtained in a time period in which targeted therapy was not 
yet implemented, and therefore we selected a control group that also had not been 
exposed to these agents. Since the overall survival of patients with metastatic colorectal 
cancer correlates with the exposure of patients to all three eff ective cytotoxic drugs (i.e. 
a fl uoropyrimidine, oxaliplatin and irinotecan) 14, we chose our control group from a 
prospective study in which the use of all these drugs was a prospective part of the study 
design 15.




Between August 1994 and December 2004, 179 patients with liver metastases were con-
sidered suitable for IHP treatment with 200mg melphalan, according to a study protocol 
approved by the medical ethical committee of the Leiden University Medical Center, as 
previously published 7, 16, 17. Of the 105 of the 179 consecutive patients with colorectal 
cancer who were actually treated with IHP, 6 patients were excluded because they were 
treated with IHP with vena porta perfusion only, a technique which has been abandoned 
17. Therefore 99 patients were included in this analysis. The data were obtained from 
a prospectively collected database and analyzed retrospectively. All IHP patients had 
measurable, irresectable colorectal metastases confi ned to the liver. Standard staging 
procedures were performed including CT scan of the chest and abdomen. Additional 
MRI or PET scans were performed if clinically indicated. Eligibility criteria included a 
WHO performance status < 2, leukocyte count ≥ 3.0 × 109/L, platelet count ≥ 100 × 109/L, 
maximum serum creatinine level 135 μmol/L, maximum serum bilirubin level 17 μmol/L 
and minimum serum albumin level 40 g/L. Exclusion criteria were age over 70 years, life 
expectancy of less than 4 months, more than 60 percent hepatic involvement of tumor 
tissue as estimated from the preoperative abdominal CT scan, coagulation disorders 
and evidence of extrahepatic metastatic disease. The interval between resection of the 
primary colorectal tumor and perfusion had to be at least 6 weeks.
Systemic treatment
Between January 2003 and December 2004, 803 patients were enrolled in the CApecitabi-
ne, IRinotecan, Oxaliplatin (CAIRO) study of the Dutch Colorectal Cancer Group (DCCG): 
a phase III randomized controlled trial comparing sequential versus combination che-
motherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer 
patients 15. Patients aged over 18 years were eligible if they had histologically proven 
advanced colorectal cancer that was in an advanced stage and not amenable to curative 
surgery, together with measurable or assessable disease parameters, and no previous 
systemic treatment for advanced disease. Previous adjuvant chemotherapy was allowed 
provided that the last administration was given at least 6 months before randomiza-
tion. Further study details have been presented 15. The primary result of the CAIRO 
study showed no signifi cant overall survival benefi t for combination versus sequential 
treatment. Therefore patients from both treatment arms were considered eligible for 
the control group of this study. Exact details on percentage of liver involvement, as was 
necessary for IHP, were not obtained.
Liselot BW.indd   78 25-10-11   11:59
Chapter 5: A case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy
79
Comparison IHP and systemic treatment
The following patients were included from the CAIRO study for comparison with IHP 
patients with liver metastases only, WHO performance status < 2, age ≤ 70 years, and 
previous resection of the primary tumor. A total of 111 patients of the CAIRO study 
fulfi lled these criteria and were included for the current analysis.
IHP treatment
The IHP technique was applied as described in the previously published articles 7, 16, 
17. In summary: melphalan 200mg (Alkeran®, GlaxoSmithKline, Zeist, The Netherlands) 
was fi rst dissolved in 40 mL Wellcome Diluent (a 60/40 (v/v) mixture of proylene glycol 
containing 5.2% (v/v) ethanol and 0·068 mol/l sodium citrate), which was subsequently 
diluted with 60 mL sterile saline. Melphalan was administered as a bolus in the isolated 
hepatic circuit and in the last 30 patients through 20 minute infusion using an infu-
sionpump (Pilote Anesthesie; Fresenius, Brezins, France) connected to the hepatic artery 
line of the isolated hepatic circuit. Leakage of perfusate into the systemic circuit was 
monitored by adding 10 MBq 99mTc-pertechnetate to the isolated circuit with subsequent 
measurement of the level of radioactivity in both the systemic and isolated circuit, as 
described previously 18, 19. If no leakage was detected, melphalan was administered; if 
leakage was calculated to exceed 10% during the perfusion period, the procedure was 
stopped and the liver was fl ushed just before this level was reached. Postoperatively, all 
patients received a daily subcutaneous dose of 480 μg granulocyte colony-stimulating 
factor (G-CSF) (Filgrastim/Neupogen®; Amgen, Breda, The Netherlands) starting the day 
after the operation until the nadir in leukocyte count was reached and the count had 
risen to more than 1.0 × 109/L. Liver and renal function tests and full blood counts were 
carried out daily in the fi rst week and henceforth as indicated by their respective levels. 
Antibiotics in a combination of cefuroxim and metronidazol were given to all patients 
for 5 days after IHP.
Systemic treatment
Eligible patients were randomly assigned to either sequential or combination treat-
ment in a 1:1 ratio, as described previously 15. All treatment cycles were administered at 
intervals of 3 weeks. In the sequential treatment group, fi rst-line treatment consisted of 
capecitabine (1250 mg/m2 twice daily) for 14 days, second-line treatment of irinotecan 
(350 mg/m2) on day 1, and third-line treatment of capecitabine (1000 mg/m2 twice daily) 
for 14 days plus oxaliplatin (130 mg/m2) on day 1. Patients assigned to combination 
treatment received capecitabine (1000 mg/m2 twice daily) for 14 days plus irinotecan 
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(250 mg/m2) on day 1 as fi rst-line treatment, and capecitabine (1000 mg/m2) twice daily 
for 14 days plus oxaliplatin (130 mg/m2) on day 1 as second-line treatment.
Statistics
All data were analyzed using SPSS (version 16.0) software and presented as mean +/- SD 
or median followed by the range. Survival was measured from the day of surgery or 
randomization until death or until the last day of follow up. Postoperative mortality was 
included in survival analysis. For discrete variables univariate analysis was performed 
with the χ2 test. Overall survival and disease progression analysis was analyzed using 
Kaplan-Meier curves, the log-rank test was used to identify diff erences in survival be-
tween groups. All tests were two-sided and p values of less than 0.05 were deemed to 
be signifi cant.
Results
Patient and treatment characteristics
In total 99 patients were treated with IHP and 111 patients were treated with systemic 
treatment. The median duration of follow up was signifi cantly shorter in the systemic 
treatment patients compared to the IHP patients, 54.7 (95% CI 48.5-60.9) versus 78.1 
(95% CI 52.1-104.2) months (P=0.004). Patient characteristics, shown in table 1, were 
similar in both treatment groups, except for age. The systemic treatment patients were 
signifi cantly older than IHP patients (P<0.01). Serum LDH, a known prognostic factor, did 
not diff er between both groups (P=0.43). The number of patients who received previous 
adjuvant chemotherapy did not diff er signifi cantly (P=0.78) from those who did not 
receive adjuvant treatment. Chemotherapy directed at liver metastases prior to IHP was 
off ered to 49 patients.
Details on IHP treatment are shown in table 2. Blood loss, operative time and duration 
of hospital stay in the IHP group were similar to previous reports 16, 17. Perioperative 
mortality was 6%, which is lower than previously published by our group, due to the 
exclusion of portal vein perfusions. Overall response rate in the IHP group was 47%. , 
and the median time to disease progression was 7.3 (95% CI 6.5-8.0) months. Sixteen 
IHP patients received adjuvant systemic treatment after IHP, while 72 patients received 
systemic treatment directed at progressive metastases after IHP. None of the patients re-
ceived bevacizumab and only one patient received cetuximab as part of the treatment.
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Details on systemic treatment in the control group of CAIRO patients are shown in table 
3. Sixty patients had been randomized to combination treatment (fi rst-line treatment 
capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin), and 51 
patients to sequential treatment (fi rst-line treatment with capecitabine, second-line 
irinotecan, and third-line capecitabine plus oxaliplatin). In the combination treatment 
group 68% of patients received both fi rst- and second-line treatment. In the sequential 
treatment group 55% of patients received all three lines of chemotherapy. Overall re-
sponse rate of fi rst-line treatment was 41%. All except four patients showed progressive 
disease during follow-up. The median time to disease progression upon fi rst-line treat-
ment was 7.9 (95% CI 6.8–8.9) months. Of the progressive patients,
26 patients showed new lesions, 44 showed an increase in preexistent lesions, 23 showed 
a combination of the above, 1 showed local recurrence and in 13 patients, the location 
of progression was unknown.






























































* Previous systemic treatment was only allowed in the IHP group. In total 49 patients in the IHP group 
received systemic treatment prior to IHP.
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Table 2. Details of IHP treatment (N=99)
Parameter Mean ± SD N(%)
Blood loss (l) 5.7 ± 4.3
Operative time (h) 9.5 ± 1.4
Hospital stay (days) 12.7 ± 6.9
Perioperative mortality 6 (6)
















Median time to progression (months), (95% CI) 7.3 (6.5-8.0)
Table 3. Details of systemic treatment in control group (N=111)























Grade 3-4 toxicities 58 (52)
Median duration of follow up (months) (95% CI) 54.7 (48.5-60.9)









Median time to progression after fi rst-line treatment 
(months) (95% CI)
7.9 (6.8-8.9)
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Overall survival
Overall survival curves are shown in fi gure 1. Median overall survival was 25.0 (95% CI 
19.4-30.6) months for the patients who were treated with IHP and 21.7 (95% CI 19.6-23.8) 
months for the patients who were treated with systemic chemotherapy only. Comparison 
of Kaplan-Meier curves by the log-rank test showed no signifi cant diff erence between 
the two treatment groups (P=0.29). Overall survival of both treatment groups was not 
infl uenced by gender, age, LDH, location of primary tumor, timing of liver metastases 
and adjuvant treatment of the primary tumor (P=0.28; P=0.31; P=0.26; P=0.88; P=0.74; 
P=0.36, respectively). Overall survival was only infl uenced by metastasectomy after 
study treatment. Median overall survival in the patients who underwent metastasec-
tomy was 47.2 (95% CI 29.5-64.9) months compared to 21.5 (95% CI 19.6-23.4) months 
in the patients who did not undergo metastasectomy (P<0.001). Metastasectomy, 
however was evenly distributed over IHP and systemic treatment arms, 6 and 9 patients 
respectively (P=0.57). Treatment-related mortality was 2% for the systemic treatment 
and 6% for IHP (P=0.11).
Figure 1. Overall survival curves of patients with liver metastases only treated with either IHP or systemic 
treatment.
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A subgroup analysis was performed of the IHP patients (N=50) who received IHP as fi rst-
line treatment (fi gure 2), to exclude any survival disadvantage due to earlier treatment 
and diagnosis of liver metastases in this group of patients. Median overall survival in this 
subgroup increased to 28.9 (95% CI 14.2-43.6) months, but was not signifi cantly diff erent 
as compared to systemic treatment (P=0.24). As the two groups have diff erent lengths 
of follow up a statistical error could arise when comparing the actuarial survival only. 
Therefore the actual 2-, 3- and 4-year survival rates were also calculated and compared. 
The 2-, 3- and 4-year survival rates for IHP patients were 53%, 28% and 14% respectively. 
The 2-, 3- and 4-year survival rates for the systemic treatment patients were 41%, 19% 
and 10% and did not diff er signifi cantly from the IHP survival rates (P=0.11; P=0.20; 
P=0.25, respectively). Similar to the actuarial survival, the 2-, 3- and 4-year survival rates 
were only infl uenced by metastasectomy.
Figure 2. Overall survival of IHP patients who did not receive systemic treatment prior to IHP compared to 
control group.
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Discussion
Over the past decade, several regional treatment options like hepatic artery infusion 
(HAI), radiofrequency ablation (RFA) and IHP have been studied extensively for the 
treatment of irresectable colorectal liver metastases. IHP has never been compared to 
systemic treatment and its defi nite role in the treatment of isolated liver metastases has 
not yet been established. To our knowledge this is the fi rst attempt to compare the out-
come of IHP with standard systemic treatment. Our study shows no signifi cant survival 
benefi t for IHP over systemic treatment with capecitabine, irinotecan and oxaliplatin.
Obviously, our study design shows several limitations. Firstly, the survival analysis is 
based on a nonrandomized case-control study. However, since it is hardly feasible to 
evaluate IHP in a prospective randomized study this approach is the best that is avail-
able. Secondly, although patient characteristics, apart from age, were evenly distributed 
between both groups, clinically relevant diff erences may still exist. In this respect it 
should be noted that IHP patients were more extensively evaluated by imaging for 
both hepatic (<60% hepatic involvement) and extrahepatic disease load. Although the 
serum LDH level was equally distributed between both groups, it cannot be excluded 
that the control group may have had extrahepatic disease upon a similar pretreatment 
evaluation. Thirdly, overall survival was calculated from the date of IHP or date of ran-
domization for systemic treatment in the control group, not from the date of diagnosis 
of liver metastases. As IHP patients were allowed to receive systemic treatment prior to 
IHP, median time from diagnosis of liver metastases to start of treatment is likely to be 
longer. To exclude any survival disadvantage a subgroup analysis was performed of the 
IHP patients who received IHP as fi rst-line treatment (N=50). Although median overall 
survival was increased in this subgroup to 28.9 months, this remained non-signifi cant 
compared to the survival in the control group.
One of the major drawbacks of IHP is the hepatotoxicity with its associated morbidity, 
largely attributable to veno-occlusive disease (VOD). In the patient cohort treated at 
our center with IHP, VOD occurred in 9-14% of patients depending on the IHP technique 
which was used 7, 16, 17. Previous phase I studies have demonstrated that VOD is the main 
dose limiting toxicity 11, 18. Another factor which limits the possible application of IHP is 
the associated perioperative mortality. Several eff orts have been undertaken to develop 
a minimal invasive technique to reduce mortality and increase effi  cacy by enabling 
repetition, but with only limited success. A few studies have been described involving 
chemofi ltration under complete hepatic venous isolation after infusion of drugs, allow-
ing administration of high doses of intrahepatic chemotherapy 20-22.
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Pingpank et al. reported a phase I study using chemofi ltration and demonstrated that 
treatment with highdose melphalan is feasible, but complete extraction of
melphalan by charcoal hemoperfusion is not possible, limiting the maximum tolerated 
dose 23. Complete isolation of the liver using minimally invasive techniques has been 
demonstrated to be technically feasible, but recently carried out phase I trials have 
shown disappointing results 24, 25. In our own center, we developed a minimal invasive 
technique using an animal model but refrained from translating this model to the clini-
cal because of doubts about the safety of the required percutaneous catheters 26.
Another option to improve current results of IHP is to incorporate some of the newly 
developed drugs for systemic treatment of colorectal cancer metastases. Zeh et. al. pub-
lished a phase I study of IHP with oxaliplatin in colorectal cancer patients 13. Dose-limiting 
veno-occlusive disease was observed at 60 mg/m2. In this study, IHP was combined 
with HAI, thereby complicating the interpretation of both toxicity and response rates. 
Moreover, the perfusate consisted of oxaliplatin monotherapy, while in systemic therapy 
combination therapy has been shown more benefi cial 27. We are currently performing a 
phase I/II trial with IHP using a combination of both melphalan and oxaliplatin.
In conclusion, our study demonstrates no survival benefi t for IHP with melphalan over 
systemic treatment with capecitabine, irinotecan and oxaliplatin. IHP should currently 
not be considered as standard treatment for patients with non-resectable colorectal 
cancer liver metastases, and should only be administered within prospective clinical 
studies.
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Abstract
In order to determine the applicability of oxaliplatin in isolated liver perfusion, we iden-
tifi ed the interaction between combinations of oxaliplatin and melphalan in 13 human 
colorectal cancer cell lines.
 Cytotoxic activity was determined by the MTT-assay. Three diff erent administration 
schedules of the two drugs were compared and median eff ect isobologram analysis 
was applied to the results to determine the presence of synergism, additive eff ects or 
antagonism as described by Chou and Talalay.
Resistance to melphalan did not correspond to resistance to oxaliplatin. All combina-
tions of melphalan and oxaliplatin showed synergistic or additive interaction in the ma-
jority of the cell lines. One hour of oxaliplatin followed by 1 hour of melphalan showed 
the lowest percentage of cell viability, with synergy in 10 out of 13 cell lines at 50% cell 
viability. Simultaneous treatment showed the highest cell viability, with antagonism in 6 
cell lines, additivity in 2 cell lines, synergism in 5 cell lines at 50% cell viability. One hour 
of melphalan followed by 1 hour of oxaliplatin showed synergy in 6 cell lines, antago-
nism in another 6 and additivity in 1 cell line.
Our fi ndings suggest a schedule-dependent synergistic interaction between melphalan 
and oxaliplatin. Therefore, oxaliplatin should be considered as a new potentially valu-
able additional agent to the currently commonly used melphalan in isolated hepatic 
perfusion in colorectal cancer patients.
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Introduction
Liver metastases are diagnosed in 10-25% of patients 1 at the time of resection of the 
primary colorectal tumor. Eventually up to 70 % of patients with colorectal cancer 
develop liver metastases. In approximately 30% of the patients the liver is the only site 
of metastatic disease 2, 3. Surgical resection is considered the standard treatment since 
complete resection can lead to curation in 25-45% of cases. However resection is only 
possible in the minority of patients due to the number, location or size of the metastases 
4-6. Isolated hepatic perfusion (IHP) is a therapeutic option for irresectable liver-only 
metastatic disease although randomized trials versus systemic therapy are lacking. The 
theoretical advantage of IHP versus systemic therapy is that IHP allows the use of high 
therapeutic dosages that would cause fatal complications if delivered systemically. 
Several drugs have been applied in IHP including 5-FU 2, 3, mitomycin C 9, 10, cisplatin 7 
and melphalan 7, 10-12, but in the past 10 years melphalan has been the only drug used in 
major clinical studies 4, 5.
In the past few years various new agents such as irinotecan, oxaliplatin, panitumumab/
cetuximab and bevacizumab, have been introduced in the systemic treatment of 
colorectal cancer, improving response rates, disease free survival and overall survival 
14-21. To improve the current standard of IHP, some of the newly developed drugs for sys-
temic treatment of colorectal cancer metastases should be considered to be used. For 
successful application in IHP such a drug has to fulfi ll several conditions. Firstly, as IHP is 
a regional treatment, the drug should be in the active form or can be transformed to its 
active agent in the liver. Secondly, increased concentrations of the drug, as compared to 
systemic treatment, should lead to an increased tumor response. Thirdly, as IHP is a short 
treatment with usually a 1 hour treatment time, the administered drug should cause 
rapid irreversible tumor cell cytoxicity. Finally, liver toxicity should be minimal. Based 
on these assumptions we considered all registered drugs for colorectal cancer. First, 
irinotecan is not an ideal candidate for IHP, since it is a prodrug and the bioactivation 
to its active metabolite SN-38 is slow6. The monoclonal antibody bevacizumab may not 
be suitable either, considering it is not directly cytotoxic and has been shown to impair 
wound healing23. Similar to bevacizumab, cetuximab/panitumumab are not directly 
cytotoxic.
Oxaliplatin was selected as the most promising new candidate for IHP based on the 
following observations Oxaliplatin is rapidly absorbed by cells and transformed by 
non-enzymatic pathways to its biologically active species. Substantial dose-dependent 
DNA adduct formation occurs within one hour24, 25. Previous studies have shown that 
in systemic administration of oxaliplatin, neurotoxicity, hematological toxicity and 
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nephrotoxicity are dose limiting, while hepatoxicity is rarely mentioned26. Phase III trials 
have shown the inferiority of oxaliplatin monotherapy versus oxaliplatin combination 
therapy27, 28, suggesting a role for the possible application of a combination of oxaliplatin 
and melphalan in IHP.
Therefore, we investigated the interaction between melphalan and oxaliplatin using 13 
human colorectal cancer cell lines.
Materials and methods
Cell culture
The human colon cancer cell lines Caco-2, Colo320, CO115, DLD-1, HCT81, HT29, Lovo, 
Ls180, Ls411n, SW480, SW48 and T84 were cultured in Hepes-buff ered RPMI-1640 cul-
ture medium supplemented with glutamine (2mN), penicillin (50U/ml), streptomycin 
(50μg/ml) and 10% (v/v) fetal calf serum (all Gibco/BRL, Paisley, UK).
Drugs
Oxaliplatin (L-OHP) was a gift from Sanofi -Aventis (Gouda, The Netherlands). Stock solu-
tions of oxaliplatin were prepared by dissolving 50mg of oxaliplatin in 10ml fetal calf 
serum-free RPMI. Melphalan (L-PAM) was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). A melphalan stock solution was prepared by dissolving 50mg melphalan in 10ml 
distilled water with 0.09% hydrochloric acid.
Cytotoxicity assay
Drug concentrations that inhibit 50% of cell growth (IC50) were determined using the 
MTT-assay, an assay designed for the spectophotometric quantifi cation of cell growth 
and cell viability 7. The cells were seeded in a 96-well microtiter-plate (Greiner, Alphen 
a/d Rijn, The Netherlands) in 200 μl culture medium at diff erent densities per cell line, 
depending on adhesion and growth qualities (Caco-2 4000 cells/well, Colo320 2000 
cells/well , CO115 1000 cells/well , DLD-1 750 cells/well , HCT81 500 cells/well, HT29 500 
cells/well, Lovo 3000 cells/well, Ls180 3000 cells/well , Ls411n 2000 cells/well, RKO 2000 
cells/well, SW480 4000 cells/well, SW48 4000 cells/well and T84 3000 cells/well). After 96 
hours, cells were treated with 100μl of nine graded concentrations of oxaliplatin (3.75-
960μM, 5.9-1500μM and 5.3-1360μM) and/or melphalan (2.3-600μM, 3.1-800μM and 
4.7-1200μM) for 1 hour, based on drug sensitivity as found in preliminary experiments 
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(unpublished data). The three combined treatment schedules of both drugs consisted 
of simultaneous, 1 hour oxaliplatin followed by 1 hour melphalan and 1 hour melphalan 
followed by 1 hour oxaliplatin drug exposure (fi gure 1). When combined, the drugs 
were tested at a constant concentration ratio for a given cell line. Combination ratios 
were determined by the IC25 of each drug and then grouped according to the sensitivity 
spectrum into 6 groups. The following ratios were used 0.88 for Caco-2, HT29, SW480, 
HCT81and Ls180; 0.27 for CO115 and RKO; 0.59 for Ls411n and T84; 0.63 for DLD-1; 0.20 
for Colo320; 0.83 for Lovo and SW48. After drug exposure cells were washed twice with 
100μl medium and 200μl fresh culture medium was added. Cells were left to grow for 72 
hours, after which culture medium was removed and cells were incubated for 4 hours 
with 100μl fresh medium and 10 μl MTT (5 mg/ml)(Sigma-Aldrich, St. Louis, MO, USA) 
labeling agent. Subsequently, 100μl solubilization solution (10% v/v in 0.01 M HCL) (Bio-
Rad, Hemel Hempstead, UK) was added and cells were left overnight for incubation. The 
absorbance at 590 nm was measured by microtiter-plate reader (BioRad Laboratories 
B.V., Veenendaal, The Netherlands). Wells containing untreated cells of the respective 
cell lines were used as controls. Each experiment was performed using three replicate 
wells. Results were expressed as the relative percentage of absorbance compared with 
controls without drug. The results were based on at least 3 independent experiments.
Analysis of combination eff ects
On the basis of the growth inhibition curve for each single drug, we analyzed the eff ects 
of diff erent treatment schedules according to the method as described by Chou and 
Talalay 8 , using the Calcusyn software program for automated analysis (Biosoft, Cam-
bridge, UK). The eff ect of combining the two drugs was evaluated by comparing the 
results of the sequential assays with the assays involving simultaneous oxaliplatin and 
melphalan treatment. The combination eff ect was evaluated by determination of the 
respective combination indexes. The combination index (CI) can be extrapolated from 
the various concentrations (C) and is defi ned as follows: CI= Coxaliplatin in combination / Coxaliplatin + 
Cmelphalan in combination / Cmelphalan + α [Coxaliplatin in combination X Cmelphalan in combination / Coxaliplatin X Cmelphalan , 
for the same eff ect (where α is the parameter with value 0 when both drugs are mutually 
Schedule A  L-PAM L-OHP  
Schedule B  L-OHP + L-PAM  
Schedule C  L-OHP L-PAM  
 -96h 0-1h 1-2h 72 h
 Plating Start treatment  MTT-assay
Figure 1 The three combination schedules of treatment of the cell lines with oxaliplatin (L-OHP) and 
melphalan (L-PAM) using a MTT assay.
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exclusive and 1 when both drugs are mutually non-exclusive. The CI indicated synergism 
if <1.0, antagonism if >1.0 and additivity if 1.0.
Results
Single-agent experiments
The cytotoxicity of melphalan and oxaliplatin was tested individually on all 13 cell lines. 
The cells were exposed to each drug for 1 hour. The IC50 values (+/- SD) are summarized 
in Table 1. For melphalan, SW48 cells were most sensitive (41 μM) and Caco-2 cells were 
most resistant (806 μM). SW48 cells were also the most sensitive to oxaliplatin (36 μM), 
CO115 cells were the least sensitive (3119 μM). Resistance to melphalan did not neces-
sarily imply resistance to oxaliplatin, as shown by Ls411n cells.
Combination experiments
Melphalan and oxaliplatin were tested in diff erent combination schedules to determine 
the most eff ective schedule. Three diff erent schedules were tested as shown in fi g. 1. The 
combination indexes (CI) at 50 % and 25 % cell viability, approximating 50 % and 75% 
cell death are given in table 2 for all treatment schedules. Simultaneous treatment with 
the two drugs resulted in antagonistic interaction in 6 cell lines, additivity in 2 cell lines 
Table 1 Cell line characteristics
Cell line Melphalan IC50 (mean value, μM) Oxaliplatin IC50 (mean value, μM)
Caco-2 806 +/- 290 562 +/- 185
CO115 592 +/- 180 3119 +/- 1777
Ls411n 576 +/- 313 298 +/- 133
HT29 316 +/- 166 548 +/- 144
SW480 190 +/- 177 947 +/-547
T84 171 +/- 85 241 +/- 92
RKO 132 +/- 65 1381 +/- 667
DLD-1 95 +/- 40  245 +/- 86
HCT81 65 +/- 20 256 +/- 121
Ls180 61 +/- 32 200 +/- 143
Colo320 61 +/- 18 541 +/- 203
Lovo 53 +/- 28 51 +/- 18
SW48 41 +/- 33 36 +/- 39
The IC50 values of melphalan and oxaliplatin are the means +/- SD of at least three independent 
experiments.
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Table 2 Combination indexes for the diff erent drug combinations
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Values are mean combination indexes (CI) of at least three independent experiments. Treatment A is 1 
hour melphalan followed by 1 hour oxaliplatin.Treatment B is melphalan and oxaliplatin simultaneously. 
Treatment C is 1 hour oxaliplatin followed by 1 hour melphalan. The CI indicates synergism if <1.0, 
antagonism if >1.0 and additivity if 1.0. †Correspond to synergistic interactions.
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and synergistic interaction in 5 cell lines at 50% cell viability. Sequential treatment with 
oxaliplatin followed by melphalan resulted in synergistic interaction in 10 cell lines and 
antagonistic interaction in the other three cell lines in nearly all ranges of cell kill fraction. 
Sequential treatment with melphalan followed by oxaliplatin resulted in antagonistic 
interaction in 6 cell lines, synergism in 6 cell lines and additive interaction in 1 cell line 
at 50% cell viability. Typical examples for CI/fractional eff ect curves are given in fi gure 2.
Discussion
Oxaliplatin has been successfully introduced in the treatment of metastatic colorectal 
cancer. Although oxaliplatin monotherapy has shown limited activity, the combination 
with 5-FU/leucovorin resulted in tumor responses in 50% of patients and a median time 
to progression of 9.0 months 16. IHP has proven a suitable treatment option for patients 
with liver-only colorectal metastases, who are not eligible for other locoregional treat-
ment options 12, 13. Over the past 10 years melphalan (with or without TNF) has been the 
major drug applied in IHP. To our knowledge the addition of new, modern agents to 
melphalan in IHP has not been investigated. Recently Herbert et al published a phase 
I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of 
unresectable liver metastases 9. In our opinion a major drawback of this study is the 
application of oxaliplatin monotherapy, since oxaliplatin monotherapy has shown only 
limited effi  cacy in the systemic treatment of colorectal cancer patients.
We examined the interaction between oxaliplatin and melphalan in a panel of 13 
colorectal cancer cell lines in vitro. The drug sensitivity spectrum of our cell lines show-
ing resistance to melphalan did not necessarily correspond to resistance to oxaliplatin, 
suggesting diff erent mechanisms of resistance for both agents. IHP melphalan mono-
therapy experience at our institution in 154 colorectal cancer patients showed an overall 
response rate of 50% on CT examinations10, suggesting resistance to melphalan in 50% 
patients. We hypothesized that this percentage can be reduced through the addition of 
oxaliplatin.
Addition of oxaliplatin to melphalan resulted in synergistic or additive interaction 
in the majority of our cell lines for all the treatment schedules. Various other in vitro 
studies have shown a schedule-dependent interaction between oxaliplatin and other 
cytostatic agents 33-36. Our experiments showed synergy especially when the cell lines 
were treated sequentially when compared to simultaneous treatment. A possible expla-
nation is the competitive uptake of both agents. The uptake of melphalan is dependent 
on active carrier-mediated transport 11. In myeloma cell lines down regulation of CD98 
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(L-phenylalanine transporter) was associated with increased resistance to and reduced 
uptake of melphalan 38. Little is known about the transport mechanisms of oxaliplatin. 
Some studies suggest the role of organic copper-transporters in the uptake of oxalipla-
tin 12-14 As simultaneous treatment with both drugs resulted in the highest cell viability 
corresponding to the least cell death, melphalan and oxaliplatin may share a common 
(competitive) transporter.
Our results also suggest that treatment with oxaliplatin, followed by treatment with 
melphalan is superior to treatment with melphalan followed by treatment with oxali-
platin. It is possible that the schedule-dependent synergistic interaction of oxaliplatin 
and melphalan would be due to inhibition by melphalan of the oxaliplatin-induced 
Pt-adducts repair mechanisms. Further experiments are necessary to identify these 
mechanisms underlying the interaction between melphalan and oxaliplatin.
In conclusion, a synergistic interaction was observed between melphalan and oxalipla-
tin. All treatment schedules showed synergistic interaction, but the best results were 
obtained if oxaliplatin treatment was followed by melphalan treatment, although the 
mechanisms of interaction remain unknown. These in vitro fi ndings provide an impor-
tant basis for a future clinical trial of the combination of oxaliplatin and melphalan in 
isolated hepatic perfusion. At our institution we are currently performing a phase I/II 
trial with IHP with a combination of oxaliplatin directly followed by melphalan.
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Abstract
To improve IHP, we performed a phase I dose-escalation study to determine oxaliplatin 
dose in combination with a fi xed melphalan dose.
Between June 2007 and July 2008, 11 patients, consisting of 8 colorectal cancer and 
3 uveal melanoma patients with isolated liver metastases, were treated with IHP with 
escalating doses of oxaliplatin combined with 100mg melphalan. Samples of blood and 
perfusate were taken for pharmacokinetic analysis and patients were monitored for 
toxicity, response and survival.
Dose limiting sinusoidal obstruction syndrome (SOS) occurred at 150mg oxaliplatin. The 
areas under the concentration-time curves (AUC) of oxaliplatin at the maximal toler-
ated dose (MTD) of 100mg oxaliplatin ranged from 11.9 mg/L x h to 16.5 mg/L x h. All 4 
patients treated at the MTD showed progressive disease 3 months after IHP.
The MTD of oxaliplatin in combination with 100mg melphalan in IHP was reached at 
100mg oxaliplatin. We think that, in view of similar and even higher doses of oxaliplatin 
applied in both systemic treatment and hepatic artery infusion (HAI), applying this dose 
in IHP will not improve treatment results in patients with isolated hepatic metastases.
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Introduction
Liver metastases are diagnosed in 10-25% of colorectal cancer patients at the time of 
primary tumour resection, while up to 70 % of patients with colorectal cancer will at 
some stage of their disease develop liver metastases 1-3. Surgical resection is considered 
the golden standard for isolated hepatic metastases, with 10-year survival rates as high 
as 17% 4. Recently, the number of patients suitable for resection has increased to up to 
60% with the introduction of new neoadjuvant systemic treatment regiments 5-9. None-
theless, a signifi cant number of patients still remain unsuitable for resection. Isolated 
hepatic perfusion (IHP) is a possible therapeutic option for irresectable liver metastases, 
but recent developments in systemic treatment in colorectal cancer have limited the 
role of IHP 10. For IHP to remain a treatment option response rates and overall survival 
need to increase, by improving both the procedure and drugs applied in IHP.
Several drugs have been applied in IHP including 5-FU 11, 12, mitomycin C 13, 14, cisplatin 
11 and melphalan 11, 14-16, but in the past 10 years melphalan has been the main drug 
used in clinical trials 16, 17. To improve the current standard of IHP, we considered some of 
the newly developed drugs for systemic treatment of colorectal cancer for application 
in IHP. As IHP is a regional treatment, the drug should be in the active form or easily 
transformed to its active agent in the liver. Preferably, this drug shows a steep dose-
response curve. Moreover, IHP is a short treatment of usually 1 hour, therefore the drug 
should cause rapid irreversible tumor cell cytoxicity. Finally, liver toxicity should be 
minimal. We evaluated all registered drugs for colorectal cancer, taking into account the 
considerations above. Irinotecan is not an ideal candidate for IHP, since it is a pro-drug 
and the bioactivation to its active metabolite SN-38 is slow18. The monoclonal antibodie 
bevacizumab, cetuximab and panitumumab may not be suitable either, because they 
are not directly cytotoxic. Therefore oxaliplatin was selected as the most promising new 
candidate for IHP. Phase III trials have shown the inferiority of oxaliplatin monotherapy 
versus oxaliplatin combination therapy19, 20, suggesting a role for the possible applica-
tion of a combination of oxaliplatin and melphalan in IHP. In vitro results showed a 
synergistic schedule dependent interaction between melphalan and oxaliplatin 21.
In this report we present the results of a phase I trial with IHP with escalating doses of 
oxaliplatin combined with a fi xed dose of 100mg melphalan.




Between June 2007 and July 2008, 11 patients with isolated liver metastases were treat-
ed with IHP with escalating doses of oxaliplatin combined with 100mg melphalan. The 
study protocol was approved by the medical ethical committee of the Leiden University 
Medical Center and informed consent was obtained from all patients. All patients had 
measurable, irresectable metastases confi ned to the liver. Standard staging studies were 
performed including CT scan of the chest and abdomen. Additional MRI or PET scans 
were performed if clinically indicated. Eligibility criteria included a WHO performance 
status of 0 or 1, leukocyte count ≥ 3.0 × 109/L, platelet count ≥ 100 × 109/L, minimum 
creatinine clearance level of 40 ml/min and maximum bilirubin level 17 μmol/L. Exclu-
sion criteria were biological age over 65 years, more than 60% hepatic replacement 
by tumour tissue as estimated from the preoperative abdominal CT scan, coagulation 
disorders or evidence of extrahepatic metastatic disease. The interval between resection 
of the primary colorectal tumour and perfusion had to be at least 6 weeks.
IHP technique
All patients were treated with IHP, consisting of an extracorporeal venovenous bypass, 
as described previously 15.
Leakage Detection
Leakage of perfusate into the systemic circuit was monitored by adding 10 MBq 99mTc-
pertechnetate to the isolated circuit with subsequent measurement of the level of 
radioactivity in both the systemic and isolated circuit, as described previously 22, 23. If 
no leakage was detected, oxaliplatin was administered. During the one hour treatment 
leakage was constantly monitored, if leakage exceeded 10% during the perfusion pe-
riod, the procedure was immediately aborted and the liver fl ushed.
Postoperative Care
All patients received a daily subcutaneous dose of 480 μg granulocyte colony-stimulat-
ing factor (G-CSF) (Filgrastim/Neupogen®; Amgen, Breda, The Netherlands) starting the 
day after the operation until the nadir in leukocyte count was reached and the count 
had risen to more than 1.0 × 109/L. Patients were monitored in the intensive care unit 
for at least 1 day after IHP. Liver and renal function tests and full blood counts were 
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carried out daily in the fi rst week and henceforth as indicated by their respective levels. 
Antibiotics in a combination of cefuroxim and metronidazol were given to all patients 
for 5 days after IHP.
Oxaliplatin and melphalan
Oxaliplatin (Sanofi -Aventis, Gouda, The Netherlands) was obtained as a ready-made 
solution and administered as a bolus in the isolated hepatic circuit. Melphalan 100mg 
(Alkeran®, GlaxoSmithKline, Zeist, The Netherlands) was dissolved in 40 mL Wellcome 
Diluent (a 60/40 (v/v) mixture of proylene glycol containing 5.2% (v/v) ethanol and 0·068 
mol/l sodium citrate), which was subsequently diluted with 60 mL sterile saline. The 
melphalan was administered as a bolus in the isolated hepatic circuit 30 minutes after 
the oxaliplatin was administered.
Dose escalation
Dose escalation depended on toxicities at the prior dose level. At least 3 patients were 
treated at each dose level. If 1of 3 patients experienced dose limiting toxicity (DLT), 3 
additional patients were entered at that dose level. DLT was defi ned as grade 4 throm-
bopenia or neutropenia for more than 7 days or febrile neutropenia or irreversible grade 
3/4 liver toxicity or other grade 3/4 non-hematological toxicity other than nausea and 
vomiting without adequate treatment. The maximal tolerated dose (MTD) was defi ned 
as the dose level below that, which induced DLT in at least one-third of the patients. (i.e., 
≥ 2 of 3 or 6 patients). Melphalan was kept at a constant dose of 100 mg, because this was 
considered standard treatment in several phase II trials 24-26. Oxaliplatin was escalated 
with 50mg at a time. Oxaliplatin was administered 30 minutes prior to melphalan based 
on in vitro fi ndings, suggesting a schedule dependent interaction between melphalan 
and oxaliplatin 21.
Toxicity
Systemic and regional toxicity were graded according to the National Cancer Institute 
Common Toxicicity Criteria version 3.0. Hepatic toxicities were considered melphalan-
related if elevations in liver function persisted beyond 7 days after perfusion, as previ-
ously suggested 16. Nonhepatic toxicities were defi ned as all toxicities that were not 
reversed within 24 hours after perfusion.
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Melphalan and oxaliplatin pharmacokinetics
Heparinized samples of all patients were taken from the perfusion medium at hepatic 
infl ow and outfl ow tracts and from the systemic circulation, at 15 diff erent time intervals 
(t=0, 1, 5, 10, 15, 20, 25, 30, 31, 33, 35, 40, 45, 50, 60 minutes). Samples were stored at 
-80 oC until analysis. All samples were analyzed by a HPLC assay as previously described 
27. The areas under the concentration-time curves (AUC) were calculated with the trap-
ezoidal rule.
Response evaluation
Objective tumour response measurements were obtained by follow up CT scans of 
the liver and remaining abdomen at 3-month intervals after treatment and at 6-month 
interval after 1 year. Additional imaging was performed if clinically indicated. RECIST 
criteria were used to determine response rates. For the RECIST criteria lesions were only 
considered measurable if ≥10mm. Complete response was defi ned as disappearance 
of all known disease, partial response as a reduction in the sum of maximal diameters 
of ≥30%, stable disease as a reduction of <30% or an increase of <20% and progres-
sive disease as an increase of ≥20% or the appearance of new intra- or extrahepatic 
lesions 28. Metastases were localized according to the Bismuth classifi cation 29. Serum 
carcinoembryonic antigen (CEA) levels were determined prior to treatment and at all 
follow-up visits.
Statistics
All data were analyzed using SPSS (version 12.0) software and presented as mean +/- 
SD or median followed by the range. All survival and disease progression analysis was 
performed by using Kaplan-Meier statistics.
Results
Patient characteristics
Demographics and tumour characteristics of the patient population are listed in Table 
1. In total 11 patients were treated with escalating doses of oxaliplatin. The liver me-
tastases originated from uveal melanoma in 3 patients and from colorectal cancer in 
the other 8 patients. Three women were treated and 8 men with a mean age of 57.9 
years (range 40-64 years). One patient was included (patient no. 5) who in retrospect 
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showed extrahepatic disease prior to IHP. Therefore 1 extra patient was included at this 
dose-level.
Treatment characteristics
Treatment characteristics are shown in Table 2. Operative time, blood loss, hospital stay 
and hepatic artery and portal vein fl ow rates and pressures are similar to the previous 
reports 17, 30. None of the patients showed more than 1 percent leakage during the entire 
procedure.





























1 F 51 Uveal 
melanoma
100 50 9.6 4.1 partial 7.6 22.1¤
2 M 64 Colorectal 
cancer
100 50 2.8 6.2 progressive - 21.9¤
3 M 54 Uveal 
melanoma
100 50 7.3 6.9 progressive - 18.7
4 M 59 Colorectal 
cancer
100 100 6.4 12.6 progressive - 4.9
5 + F 40 Colorectal 
cancer
100 100 15.4 16.5 - - 5.5
6 F 61 Uveal 
melanoma
100 100 10.3 16.5 progressive - 7.8
7 M 63 Colorectal 
cancer
100 100 2.8 11.9 progressive - 18.2¤
8 M 63 Colorectal 
cancer
100 150 6.7 19.6 partial 6.5 12.0¤
9 M 63 Colorectal 
cancer
100 150 4.8 16.7 partial 11.1 13.9¤
10 * M 57 Colorectal 
cancer
100 150 9.9 20.6 - - 0.5
11 * M 62 Colorectal 
cancer
100 150 6.5 18.2 - - 1.0
+ In retrospect patient showed extrahepatic metastases prior to IHP, which were immediately progressive 
after IHP.
* Both patients died perioperatively. Patient no. 10 due to excessive bleeding and patient no. 11 due to 
hepatotoxicity.
¤ Patients were still alive at the end of follow up.
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Pharmacokinetics
Samples for pharmacokinetical analysis were successfully collected from each patient. 
Individual data of the AUC of both melphalan and oxaliplatin are shown in table 1. 
Escalating doses of oxaliplatin corresponded to an increasing AUC, with the maximum 
of 20.6 mg/L x h achieved at the highest dose level of 150mg oxaliplatin. The maximum 
peak concentration of oxaliplatin was 40.8 mg/L and was achieved in patient no 9, also 
at the highest dose level. Little diff erence was observed between the oxaliplatin con-
centrations in the hepatic infl ow and outfl ow tract, as shown in fi gure 1, suggesting only 
limited hepatic extraction of oxaliplatin.
Toxicity and complications
Major complications occurred in 4 patients of which 2 patients died perioperatively. 
One perioperative death was due to massive blood loss, while the other perioperative 
death was due to hepatotoxicity as a result of sinusoidal obstruction syndrome (SOS). 
The perioperative death due to massive blood loss was attributed to the procedure and 
not toxicity. Therefore another patient was included at this dose-level. Toxicity levels 
according to dose-level are shown in Table 3. Reversible grade 3-4 hepatoxicity occurred 
in 7 patients. DLT consisted of irreversible grade 4 hepatotoxicity requiring hepatic-
replacement therapy due to SOS and was reached at 150mg oxaliplatin combined with 
100mg melphalan.
Table 2 Treatment parameters 
Parameter Mean ± SD n
Flow rate hepatic artery (mL/min) 293.9 ± 68.1
Flow rate portal vein (mL/min) 312.8 ± 31.3
Pressure hepatic artery (mm/Hg) 129.4 ± 20.0
Pressure portal vein(mm/Hg) 49.1 ± 4.0
Percentage leakage during perfusion 0.4 ± 0.5
Blood loss (L) 5.5 ± 5.8
Operative time (hr) 8.4 ± 1.6
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Figure 1. Typical examples of concentration time curves of oxaliplatin for each dose-level (A= 50mg 
oxaliplatin, B= 100mg oxaliplatin, C=150mg oxaliplatin). Increasing dose-levels show increasing peak 
concentrations of oxaliplatin. All concentration curves show a gradual decline over time.
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Tumour response and patient survival
Of the 5 patients with colorectal cancer with an elevated CEA prior to IHP, three showed 
50% or more reduction in CEA after IHP. Only 8 patients were available for response 
evaluation of which 3 patients showed a partial response according to the RECIST cri-
teria. After a median follow up of only 18.2 months (95% CI; 10.5-26.0 months), median 
overall survival was 18.7 months (95% CI; 1.7-35.7 months) including 3 uveal melanoma 
patients..
Discussion
In this study we evaluated escalating doses of oxaliplatin combined with a fi xed dose of 
100mg melphalan in an isolated hepatic perfusion circuit for patients with metastatic 
Table 3 Toxicity according to National Cancer Institute Common Toxicity Criteria version 3.0 (n=11)
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Leukocyte nadir
- Dose level I 3 0 0 0 0
- Dose level II 4 0 0 0 0
- Dose level III 4 0 0 0 0
Bilirubin
- Dose level I 2 1 0 0 0
- Dose level II 2 0 0 1 1
- Dose level III 0 0 0 2 2
Alkaline phosphatase
- Dose level I 1 2 0 0 0
- Dose level II 0 1 2 0 1
- Dose level III 0 2 2 0 0
Alanine aminotransferase
(ALAT)
- Dose level I 2 0 0 1 0
- Dose level II 1 1 1 0 1
- Dose level III 0 1 2 0 1
Asparate aminotransferase (ASAT)
- Dose level I 0 1 2 0 0
- Dose level II 0 2 0 2 0
- Dose level III 0 1 1 1 1
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disease limited to the liver. DLT, consisting of SOS, occurred at a relatively low dose level 
of 150mg oxaliplatin.
In previous IHP studies DLT also consisted of SOS as one of the main limitations of IHP 
with melphalan 15, 16. Nonetheless, we did not expect DLT to occur at such a low dose 
of oxaliplatin, especially considering the 50% reduction in melphalan compared to our 
previous trials17, 31. At the time of development of this study protocol, oxaliplatin was 
considered a non-hepatotoxic drug, with only limited hepatoxicity reported in both 
systemic and hepatic arterial infusion (HAI) trials 32-36. This observation combined with 
the synergistic interaction between melphalan and oxaliplatin, as demonstrated by 
our previously published in vitro data, was the foundation of the development of this 
study protocol 37. More recently however, after development of our study protocol, an 
increasing number of studies have reported on the hepatotoxicity, especially the risk of 
SOS, after treatment with oxaliplatin prior to hepatectomy of colorectal liver metastases. 
Incidence rates of SOS have been reported of up to 59% and oxaliplatin-based chemo-
therapy has been shown an independent risk factor for complications associated with 
hepatectomy with confl icting data concerning impact on both morbidity and mortality 
38-42. In view of the above, the addition of a cytostatic agent with a high incidence of SOS 
to a procedure with already a high risk of SOS, can explain the occurrence of DLT at only 
150mg of oxaliplatin.
Similarly to our study, Zeh et. al. published a phase I study of IHP with oxaliplatin , but 
instead of oxaliplatin combination therapy, the perfusate consisted of oxaliplatin mono-
therapy, while in systemic therapy combination therapy has been shown more eff ective 
19, 43. Dose-limiting toxicity, also consisting of SOS, was observed at only 60 mg/m2, again 
indicating the high potential of inducing SOS if oxaliplatin is applied in isolated hepatic 
perfusion circuit, irrespective of combination with other agents. This study reported an 
overall response rate of 66%, but IHP was combined with HAI, complicating the inter-
pretation of both toxicity and response rates. In our study meaningful interpretation 
of the response rate is complicated because of the phase I design and the inclusion of 
both uveal melanoma and colorectal cancer patients. Of the 8 colorectal cancer patients 
included, only two patients showed a partial response, both were treated at the highest 
dose level of 150mg oxaliplatin. All patients treated at the MTD of 100mg oxaliplatin 
showed progressive disease 3 months after IHP. Considering the dose of oxaliplatin used 
in regular systemic combination treatment in colorectal cancer patients of over 100mg/
m2 per treatment cycle, conducting a phase II IHP trial based on the MTD dose of 100mg 
oxaliplatin seems hardly benefi cial.
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Although the Cmax in our study was higher than the Cmax reported after a 2-hour infu-
sion of oxaliplatin 130mg/m2 in systemic trials, the AUC of oxaliplatin at the MTD in our 
study ranging from 11.9 mg/L x h to 16.5 mg/L x h was similar to the AUC reported in 
systemic trials44. A possible survival benefi t for IHP over systemic treatment can only 
be achieved at this dose if response to oxaliplatin therapy is concentration- rather than 
dose-dependent. Our previous experience with melphalan showed that an increase 
in melphalan concentration did not increase response rates, but did increase toxicity 
31. Moreover, current HAI study protocols already apply a dose of oxaliplatin of up to 
150mg/m2 32-36. Similarly to IHP, HAI off ers the advantage of high concentrations of the 
cytostatic agent in the liver, but contrary to IHP, HAI is a minimally invasive procedure 
and is suitable for repetitive treatment, further limiting the possible role of oxaliplatin 
in IHP.
In conclusion, we have established the MTD of oxaliplatin in combination with 100mg 
melphalan in IHP at 100mg. Further escalation is limited by the occurrence of SOS. In 
view of similar and even higher doses of oxaliplatin applied in both systemic treatment 
and HAI, applying this dose in IHP will not result in further improvement of treatment of 
patients with isolated hepatic metastases.
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Introduction
Worldwide colorectal cancer is the third most common cause of cancer related deaths 
with approximately 639000 deaths each year (WHO fact sheet 297). In approximately 
30% of colorectal cancer patients the liver is the only site of metastatic disease 1, 2. 
Complete surgical resection is considered the best treatment with 5-year survival rates 
ranging from 25-51%. Unfortunately, surgical resection is only possible in less than 10 
percent of patients due to the number, location or size of the metastases 3-5. Recently, 
neoadjuvant chemotherapy has been introduced, rendering another 10 to 30 % of 
patients resectable 6. The management of irresectable colorectal liver metastases, on 
the other hand, remains a challenge for all cancer specialists. Recent studies have shown 
improved survival with the introduction of oxaliplatin, irinotecan, bevacizumab and 
cetuximab in the systemic treatment of colorectal metastases 7-12. Regional treatment 
options however, can off er the potential benefi t of both aggressive local treatment and 
limited systemic toxicity. Several regional therapies have been developed including 
isolated hepatic perfusion (IHP). IHP, a technique which involves complete vascular 
isolation of the liver, allows for high local drug exposure. Phase II studies involving IHP in 
colorectal cancer patients have shown hepatic response rates up to 74% with a median 
time to hepatic progression up to 14.5 months, a median overall survival of 27 months 
and 5 year survival of 9%13-17.
Advancing role of systemic treatment
When IHP was fi rst introduced, the standard treatment for metastatic colorectal cancer 
consisted of 5-FU based schedules, resulting in response rates around 15%, median time 
to progression of 5 months and overall survival of 12 months 18. Recently, several new 
agents have become available including oxaliplatin, irinotecan and the monoclonal an-
tibodies bevacizumab and panitumumab/cetuximab 8-12, 19-21. The introduction of irino-
tecan and oxaliplatin combined with 5-FU/leucovorin or capecitabine has increased me-
dian progression free surivival and overall survival from approximately 5 and 12 months 
to approximately 9 and 17 months, respectively 9, 11, 22-26. If both treatment schedules are 
combined even better results have been reported. Tournigand et al conducted a phase 
III cross-over study of fi rst-line chemotherapy with in one arm 5-FU/leucovorin with 
oxaliplatin and in the other arm 5-FU/leucovorin with irinotecan resulting in maximum 
medium survival after both treatments of 21.5 months 12. Koopman et al showed that 
both combination treatment and sequential treatment with capecitabine, irinotecan and 
oxaliplatin yields similar results 27. Even more recently, the monoclonal antibodies have 
been introduced for the treatment of colorectal cancer. Hurwitz et al reported that the 
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addition of bevacizumab, a monoclonal antibody directed against vascular endothelial 
growth factor (VEGF), to bolus irinotecan and 5-FU/leucovorin as a fi rst-line treatment 
resulted in increase of progression free survival to 10.6 months and overall survival to 
20.3 months 10. Similarly, panitumumab/cetuximab, monoclonal antibodies against epi-
dermal growth factor receptor (EGRF), have also improved survival in combination with 
either irinotecan or oxaliplatin, especially in patients without K-ras mutations 19, 21. At the 
moment the combination of fl uoropyrimidine-based chemotherapy with oxaliplatin and 
bevacizumab is considered standard fi rst-line treatment in metastatic colorectal cancer, 
while irinotecan schould be reserved for second-line treatment and panitumumab or 
cetuximab for third-line treatment for patients with wild type K-ras 28, 29.
Most treatment schedules described above can be given safely prior to and after 
IHP without increasing the toxicity of IHP (Chapter 4), rendering IHP both a possible 
fi rst-line or second- and even third-line treatment option after systemic treatment. 
The question remains whether systemic treatment alone can achieve similar or even 
better results in the selected group of patients with liver metastases only, eligible for 
IHP. We compared IHP in 99 patients with 105 patients who received a combination of 
capecitabine, oxaliplatin and irinotecan (Chapter 5). There was no signifi cant diff erence 
in overall survival between IHP and systemic treatment (25.0 months vs. 21.7 months; 
p=0.29). However, this study was complicated by several drawbacks. Overall survival was 
calculated from the date of randomization for systemic treatment and date of surgery 
for IHP, but not from the date of diagnosis of liver metastases. Contrary to the systemic 
treatment patients, the IHP patients were allowed to receive systemic treatment prior 
to the start of the study treatment. Therefore, it is likely the IHP patients suff ered from 
a relative survival disadvantage as compared to the systemic treatment patients. We at-
tempted to exclude some of this disadvantage by performing a subgroup analysis of the 
IHP patients who received IHP as fi rst-line treatment. Although overall survival increased 
to 28.9 months, still no signifi cant diff erence in survival could be demonstrated. Prob-
ably, the lack of a statistically diff erent survival advantage can be mainly attributed to 
the high mortality in the fi rst few months after IHP.
For IHP to remain a treatment option for isolated liver metastases, perioperative mortal-
ity needs to be reduced or new agents with better responses need to be introduced. 
Possibly, in view of the developments in systemic treatment, IHP should be abandoned 
completely for the treatment of colorectal liver metastases and the application of IHP in 
metastases from various other origins further explored.
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Improving the technique, reducing the mortality
The IHP procedure, as currently performed at our center, is a diffi  cult technique with a 
relatively high mortality and considerable morbidity. Several eff orts have been under-
taken to develop minimally invasive procedures for IHP, but with only limited success. 
Chemofi ltration has been used to allow for high doses of intrahepatic chemotherapy 
without systemic toxicity 30-32. After the drug is infused in the hepatic artery, the hepatic 
venous blood is bypassed to a charcoal hemoperfusion fi lter for extracorporeal drug 
elimination before it returns to the patients’ systemic circulation. A phase I study using 
the technique described above, demonstrated that treatment with high-dose melphalan 
is feasible. Nevertheless, complete extraction of melphalan by charcoal hemoperfusion 
is not possible, limiting the maximum tolerated dose 33. At our center, we demonstrated 
complete isolation of the liver using minimally invasive techniques to be technically 
feasible in pigs, but recently performed phase I trials at other centers have shown disap-
pointing results 34, 35. Savier et al. reported a repetitive IHP procedure, in which the fi rst 
course was given at laparotomy and the next two courses with the new percutaneous 
technique 36. At the initial laparotomy a catheter in the gastroduodenal artery was 
inserted which during subsequent percutaneous treatment was used to administer the 
melphalan. Although they achieved an isolated hepatic perfusion circuit, considerable 
leakage to the systemic circulation occurred during IHP. Another study published by 
van Etten et al reported a phase I-II study in 18 patients 37. In the fi rst 8 patients vascular 
isolation was attempted through occlusion of the portal vein with outfl ow through 
the hepatic veins into an intracaval double-balloon catheter, resulting in on average 
56% leakage. The following 10 patients were treated with a diff erent technique using 
retrograde outfl ow perfusion, with a triple balloon blocking outfl ow into the caval vein 
and allowing outfl ow via the portal vein. The last technique resulted in less leakage, 
but retrograde perfusion was still complicated by 35% leakage on average, limiting the 
possible applications of this technique. Recently Verhoef et al. published a study on 
an alternative simplifi ed technique for IHP. 38. A new technique using a retrograde he-
patic fl ow in an isolated hypoxic hepatic perfusion was applied. In total 24 patients were 
treated with irresectable liver metastases of various origin. Operation time and blood 
loss were considerably less as compared to classical IHP and no perioperative mortality 
was observed. Although the method described above was open procedure not suitable 
for repetition it seems the most promising of the recent developments, considering the 
leakage control and reduction in mortality.
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Introducing new agents
The past decade melphalan has been the main drug applied in IHP. The application of 
new agents in IHP might improve response rates and increase overall survival. Before, we 
examined new agents, we tried to improve effi  cacy by changing the administration of 
melphalan (Chapter 3). To achieve high local concentrations, we administered 200 mg 
of melphalan through a 20-minute infusion in the hepatic artery, instead of the previ-
ously performed bolus administration. Although we achieved high local concentrations 
in 30 patients for an increased period of time, toxicity increased without improvement 
of survival or response rates. We concluded that while response is probably dose-
dependent, toxicity is mainly concentration-dependent. Therefore we abandoned this 
technique and directed our eff orts towards exploring new agents.
New agents for IHP have to fulfi l at least three conditions. Firstly, the drug has to cause 
rapid tumour cell destruction, due to the 1-hour nature of the procedure. Secondly, 
the drug has to be a direct working agent and thirdly, ideally the agent has a steep 
dose-response curve. Of the drugs recently introduced for the systemic treatment of 
colorectal cancer, only oxaliplatin fulfi ls all these conditions. Zeh et al. published a phase 
I study of IHP with oxaliplatin in colorectal cancer patients 39. Dose-limiting veno-occlu-
sive disease was observed at 60mg/m2. In this study, however IHP was combined with 
HAI complicating the interpretation of both toxicity and response rates. Moreover, the 
perfusate consisted of oxaliplatin monotherapy, while in systemic therapy combination 
therapy has been shown more benefi cial 40. Therefore, we studied the combination of 
oxaliplatin with melphalan. In vitro results show a schedule dependent synergistic inter-
action between these two agents (Chapter 6). Recently, we performed a phase I trial in 
11 patients with IHP with escalating doses of oxaliplatin followed by 100mg melphalan 
(Chapter 7). Dose-limiting-toxicity, consisting of sinusoidal obstruction syndrome (SOS), 
was achieved at only 150mg oxaliplatin combined with 100mg melphalan. Currently, 
the dose of oxaliplatin used in regular systemic combination treatment in colorectal 
cancer patients exceeds 100mg/m2 per treatment cycle. Therefore conducting a phase II 
IHP trial based on the MTD dose of 100mg oxaliplatin seems hardly benefi cial. Moreover, 
HAI study protocols already apply a dose of oxaliplatin of up to 150mg/m2 and contrary 
to IHP the procedure is suitable for repetition 41-45. In view of this we believe that further 
exploration of the application of oxaliplatin in IHP will not improve treatment results.
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Finding new applications
While the application of IHP in colorectal cancer patients has been thoroughly explored, 
little is known about the application in liver metastases from other primary tumours. 
Possibly a new role can be found for IHP in isolated liver metastases from a variety of 
tumours. Neuroendocrine tumours and uveal melanomas, although rare, are the second 
most common origin of metastases confi ned to the liver46.
In neuroendocrine cancer metastases results of systemically administered agents have 
been disappointing with response rates around 30-40% for cytostatic drugs and 11% 
for interferon-α 47-49. Symptomatic relief can be achieved through somastatin analogs 
such as octreotide. Symptomatic improvement occurs in up to 70% of patients, but 
objective tumour response is less than 10% and drug resistance can develop in 3-12 
months 50-53. Grover et al. reported the experience with IHP in 13 neuroendocrine cancer 
patients with a overall response rate of 50% and median progression free survival of 7 
months 54. The nature and incidence of major complications and mortality was similar 
to other trials independent of primary origin of liver metastases. At our center we have 
only treated two patients with liver metastases from neuroendocrine carcinoma, one 
patients showed stable disease, while the other patient showed a partial response for 
33.4 months (Chapter2).
For the treatment of metastatic uveal melanoma no standard systemic agent currently 
exists. Several studies have reported response rates of less than 10% to conventional 
systemic chemotherapy 55, 56. Results with immunotherapy, as for example interferon-α 
and interleukin-2, are equally disappointing with no or only minor responses 57, 58. Alex-
ander et al reported the results of IHP with 1.5mg/kg melphalan in 29 uveal melanoma 
patients. Hepatic response rate was 62% with a progression-free survival of 8 months 
and an overall survival of 12.1 months. In our patients the response rate was less; only 
33%, but 50% of patients did show stable disease with a median time to progression of 
6.6 months and an overall survival of 10 months similar to the results of Alexander et 
al. (Chapter 2). Although these results may seem disappointing as compared to IHP in 
other primary tumours, there is a survival benefi t compared to a median survival of 2 
months in uveal melanoma patients with liver metastases without antitumour treatment 
59. Moreover, we have no accepted alternative treatment options for uveal melanoma 
patients with irresectable isolated liver metastases. Recently, at the 2010 ASCO annual 
meeting Pingpank et al. presented a phase III study in 92 malignant melanoma patients 
with hepatic metastases randomly assigned to either percutaneous hepatic perfusion 
with melphalan or standard of care. Median hepatic progression free survival was 245 
days for the perfusion group and 49 days for the standard care group (p<0.001). Cur-
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rently we are looking into the application of new agents in IHP for uveal melanoma 
patients. Peters et al reported the use of HAI with fotemustine, an alkylating agent, in 
101 uveal melanoma patients with liver metastases 60. Fotemustine was infused in the 
hepatic artery for a 4-week induction period followed by a maintenance treatment every 
three weeks until disease progression. The overall response rate was 36%, with a median 
overall survival of 15 months and a 2-year survival rate of 29%. Although the response 
rate of fotemustine infusion is similar to our results with IHP in uveal melanoma patients, 
the overall survival of 15 months seems superior to our observed 10 months. Possibly, in 
future IHP trials fotemustine can be introduced.
Conclusion
Although IHP made a promising start in the early 90s, currently it is faced by many chal-
lenges. In view of recent developments in systemic treatment, the absence of signifi cant 
improvement of the technique and the lack of new applicable agents, IHP should not be 
considered a standard treatment option for colorectal cancer patients with isolated liver 
metastases. Possibly, a role still exists for IHP in the treatment of liver metastases from 
non-colorectal cancer origin. Whether under these circumstances, IHP can still attract 
the interest of both clinical and surgical oncologists necessary for further improvements, 
remains the question.
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Nederlandse samenvatting
Colorectale kanker (kanker aan de dikke darm of endeldarm) is de belangrijkste oor-
zaak van uitzaaiingen (metastasen) naar de lever. Uiteindelijk ontwikkelt 70% van de 
patiënten met colorectale kanker uitzaaiingen naar de lever. Echter, bij slechts 30% van 
de patiënten zijn deze uitzaaiingen beperkt tot alleen de lever. Bij deze laatste groep 
patiënten is genezing in theorie mogelijk, indien de uitzaaiingen operatief worden ver-
wijderd. Helaas is dit bij de meeste patiënten niet mogelijk aangezien de locatie, grootte 
of aantallen van de uitzaaiingen dit onmogelijk maakt. Gelukkig zijn er de laatste jaren 
verschillende behandelingen ontwikkeld om zowel de kwaliteit als de duur van het 
leven van patiënten met leveruitzaaiingen van colorectale kanker te verbeteren.
In hoofdstuk 1 beschrijven we de verschillende behandelingsmogelijkheden voor le-
vermetastasen van colorectale kanker. Naast chemotherapie in de algemene bloedbaan 
(systemisch) bestaan er verschillende locale behandelingsmogelijkheden waaronder 
de geïsoleerde leverperfusie (IHP). IHP is een techniek waarbij de aan- en afvoerende 
vaten van de lever tijdelijk afgesloten worden, opdat een gesloten circuit ontstaat. De 
afscheiding van de lever van de algemene bloedbaan maakt het mogelijk om lokaal een 
hoge dosis chemotherapie toe te dienen. Gedurende deze procedure wordt de lever van 
zuurstof voorzien door een pomp met een oxygenator en wordt de lekkage van het che-
motherapeuticum naar de algemene bloedbaan geregistreerd. Na rondpompen van het 
chemotherapeuticum, meestal gedurende 1 uur, wordt de lever gespoeld met schoon 
kunstbloed. Uiteindelijk wordt de oorspronkelijke vaatvoorziening weer hersteld. IHP 
wordt sinds een aantal jaren in een beperkt aantal centra in de wereld toegepast. In het 
Leids Universitair Medisch Centrum (LUMC) is al bijna twintig jaar ervaring met deze 
techniek en zijn meer dan 130 patiënten behandeld met IHP. Na een fase I studie van 
IHP, waarbij een dosisescalatie studie is gedaan met melfalan is in 1994 een fase II studie 
gestart. Evaluatie van de eerste 66 patiënten van de fase II studie lieten bij meer dan 50% 
van de patiënten een gedeeltelijk of zelfs compleet verdwijnen van de metastasen zien. 
Echter, IHP is een ingrijpende procedure met veel complicaties die zelfs bij 5-6% van 
de patiënten leidt tot de dood. Aanvankelijk, toen IHP werd ontwikkeld was er slechts 
beperkte systemische behandeling van levermetastasen mogelijk. De laatste 10 jaar zijn 
er verschillende nieuwe chemotherapeutica geïntroduceerd voor de behandeling van 
levermetastasen van colorectale kanker, met goed resultaat. Gezien deze ontwikkelin-
gen is het de vraag of IHP in zijn huidige hoedanigheid nog een plek verdient binnen 
de behandeling van patiënten met levermetastasen. Mogelijk kan de positie van IHP 
verbeterd worden door een verbetering van de techniek, de introductie van nieuwe 
chemotherapeutica of het ontdekken van nieuwe toepassingen.
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In hoofdstuk 2 beschrijven we de toepassing van IHP met melfalan bij een nieuwe groep 
patiënten. In het totaal zijn 19 patiënten met leveruitzaaiingen niet afkomstig van colo-
rectale kanker behandeld met IHP. Dertien patiënten hadden uitzaaiingen van oogme-
lanoom, 2 patiënten van neuroendocriene tumoren, 2 patiënten van gastro-intestinale 
stromale tumoren, 1 patiënt van weke delen kanker en 1 patiënt had leverkanker. Van 
de oogmelanoom patiënten reageerde 33% op de behandeling gedurende gemiddeld 
6.6 maanden. De gemiddelde overleving was 10 maanden. Hoewel deze cijfers teleur-
stellend lijken dient in ogenschouw genomen te worden dat het natuurlijk beloop van 
oogmelanoom veel slechter is dan dat van colorectale kanker en dat in tegenstelling tot 
colorectale kanker er geen alternatieve behandelingsmogelijkheden zijn. Van de ove-
rige patiënten reageerde 50% op de behandeling, waarbij opgemerkt dient te worden 
dat bij de patiënt met weke delen kanker bij beeldvorming helemaal geen uitzaaiingen 
meer zichtbaar waren. Mogelijk kunnen deze resultaten nog verbeterd worden indien 
een ander middel wordt gebruikt dan melfalan, specifi ek voor deze vormen van kanker.
In hoofdstuk 3 worden de resultaten beschreven van een nieuwe IHP techniek waarbij 
het chemotherapeuticum niet in één keer aan het gesloten circuit wordt toegediend, 
maar geleidelijk via de slagader de lever wordt ingespoten. Uit eerdere studies weten 
we dat indien melfalan in één keer aan het systeem wordt toegediend er slechts voor 
korte tijd een hoge concentratie wordt bereikt. Door het geleidelijk aan toedienen van 
melfalan werd getracht een hoge concentratie voor langere tijd te bereiken, om de eff ec-
tiviteit van de behandeling te vergroten. In het totaal zijn 30 patiënten met levermeta-
stasen van colorectale kanker behandeld met deze nieuwe techniek. Farmacokinetische 
analyses lieten inderdaad een hoge concentratie gedurende een wel 2 keer zo lange tijd 
als bij de reguliere perfusies zien. Echter, veel meer patiënten hadden complicaties in 
vergelijking tot de reguliere procedure, terwijl bij minder patiënten de levermetastasen 
reageerden op de behandeling. Hoogstwaarschijnlijk worden de gezonde levercellen 
eerder beschadigd door de hoge concentratie dan de kankercellen. Daarnaast kunnen 
bij deze procedure door de technische beperkingen slechts lage drukken worden be-
reikt, mogelijk dat een hogere druk (zoals bij de reguliere procedure) nodig is om bij de 
kankercellen te komen.
In hoofdstuk 4 worden de resultaten van alle patiënten met colorectale kanker be-
schreven die tussen augustus 1994 en december 2004 behandeld zijn met IHP in het 
LUMC. Gekeken werd of er prognostische factoren geïdentifi ceerd konden worden die 
een betere patiëntenselectie mogelijk maakt. In het totaal werden in deze periode 105 
patiënten behandeld door middel van IHP. De perioperatieve mortaliteit was 7%. De 
uitzaaiingen in de lever werden kleiner of verdwenen bij 50% van de patiënten voor 
gemiddeld 7.4 maanden. De gemiddelde overleving na de leverperfusie was 24.8 maan-
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den. De patiënten met meer dan 10 levermetastasen, postoperatieve complicaties of bij 
wie het technisch niet gelukt was om zowel de ader als de slagader te gebruiken voor de 
perfusie overleefden signifi cant korter. Bovendien viel op dat in retrospect, bij 7% van 
de patiënten ook uitzaaiingen buiten de lever aanwezig waren voor IHP, wat mogelijk 
voorkomen had kunnen worden door betere beeldvorming voor de IHP.
Hoewel al jaren onderzoek wordt verricht naar de geïsoleerde leverperfusie, is het ondui-
delijk of in deze kleine, geselecteerde groep patiënten vergelijkbare resultaten behaald 
kunnen worden met alleen chemotherapie. In hoofdstuk 5 vergelijken we de resultaten 
van een controle groep van 111 patiënten met alleen levermetastasen die chemothera-
peutische behandeling heeft ondergaan met een groep van 99 patiënten die een lever-
perfusie heeft ondergaan. De groepen patiënten waren vergelijkbaar met betrekking 
tot geslacht, performance status, LDH en lokalisatie van primaire tumor. Echter de IHP 
groep was signifi cant jonger dan de groep patiënten met alleen systemische behande-
ling. Bovendien was er een verschil in voorbehandeling van beide patiëntgroepen; de 
helft van de leverperfusie patiënten was voorbehandeld met chemotherapie terwijl in 
de controlegroep geen enkele patiënt voorbehandeld was. De algemene gemiddelde 
overleving was 21.7 maanden voor systemische behandeling en 25 maanden voor de 
leverperfusie, maar er was geen sprake van een statisch signifi cant verschil. Ondanks 
de methodologische beperkingen van deze studie, kan geconcludeerd worden dat de 
leverperfusie geen extra overlevingsvoordeel biedt ten op zichten van alleen chemo-
therapeutische behandeling. Overigens, dient er een gerandomiseerde trial verricht te 
worden, indien men deze conclusie defi nitief zou willen bevestigen, maar dit lijkt zowel 
onethisch als praktisch moeilijk realiseerbaar.
In hoofdstuk 6 worden de resultaten beschreven van onderzoek naar de combinatie 
van melfalan met oxaliplatin in 13 verschillende colorectale kanker cellijnen. Er werd 
gekeken naar celdood bij verschillende concentraties van melfalan tegelijk toegediend 
met oxaliplatin, oxaliplatin gevolgd door melfalan en melfalan gevolgd door oxaliplatin. 
De resistentie voor melfalan kwam niet noodzakelijkerwijs overeen met de resistentie 
voor oxaliplatin. Indien oxaliplatin voor melfalan wordt toegevoegd versterken beide 
middelen elkaar in 11 van de 13 cellijnen bij 75% celdood. Er blijkt dus een schema-
afhankelijke positieve interactie te zijn tussen melfalan en oxaliplatin.
In hoofdstuk 7 wordt een klinische studie beschreven waarin de resultaten uit hoofd-
stuk 7 worden toegepast. In het totaal zijn 11 patiënten behandeld met leverperfusie 
met een oplopende dosis van oxaliplatin gevolgd door een vaste dosis melfalan. Dosis-
beperkende toxiciteit werd reeds gevonden bij 150mg oxaliplatin gevolgd door 100mg 
melfalan.
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Hoofdstuk 8 vat kort de ontwikkelingen samen op het gebied van de geïsoleerde 
leverperfusie. Geconcludeerd wordt dat gezien het ontbreken van overlevingswinst van 
IHP ten op zichten van de huidige chemotherapeutische behandeling het maar zeer de 
vraag is of er een toekomst is voor IHP. Indien IHP een eff ectieve bijdrage wil leveren aan 
de behandeling van patiënten met geïsoleerde levermetastasen dan dienen zowel de 
procedure als de toegepaste middelen verder te worden verbeterd. 
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